

1     **Deep cervical lymph nodes of patients with multiple sclerosis show**  
2             **dysregulated B cells in the presence of Epstein-Barr virus**

3     **Authors:**

4     Joonas Sarkkinen<sup>1,\*†</sup>, Dawit Yohannes<sup>1,†</sup>, Nea Kreivi<sup>1</sup>, Pia Dürnsteiner<sup>1</sup>, Jani  
5     Huuhtanen<sup>1-4</sup>, Kirsten Nowlan<sup>1</sup>, Goran Kurdo<sup>5</sup>, Riikka Linden<sup>5</sup>, Mika Saarela<sup>6</sup>, Pentti J  
6     Tienari<sup>1,6</sup>, Eliisa Kekäläinen<sup>1</sup>, Maria Perdomo<sup>7</sup>, Sini M Laakso<sup>1,6,\*</sup>

7  
8     **Affiliations:**

9     <sup>1</sup> Translational Immunology Research Program, University of Helsinki, Helsinki, Finland

10    <sup>2</sup> Hematology Research Unit Helsinki, Department of Hematology, University of Helsinki  
11    and Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland

12    <sup>3</sup> ICAN Digital Precision Cancer Medicine Flagship, University of Helsinki and Helsinki  
13    University Hospital Comprehensive Cancer Center, Helsinki, Finland

14    <sup>4</sup> Department of Computer Science, Aalto University School of Science, Espoo, Finland

15    <sup>5</sup> Department of Radiology, University of Helsinki and Helsinki University Hospital,  
16    Helsinki, Finland

17    <sup>6</sup> Department of Neurology, Brain Center, Helsinki University Hospital, Helsinki, Finland

18    <sup>7</sup> Department of Virology, University of Helsinki and Helsinki University Hospital,  
19    Helsinki, Finland

20    † Equal contribution

21    \* Corresponding author

22

23 **Abstract:** Despite the recognized role of Epstein-Barr virus (EBV) in predisposing to  
24 multiple sclerosis (MS) and the effectiveness of B cell-depleting therapies in MS, the  
25 mechanism of autoimmunity remains elusive. Using fine needle aspirations, we  
26 investigated deep cervical lymph nodes (dcLNs), the primary site of the adaptive  
27 immune response against EBV, in newly diagnosed untreated MS patients and healthy  
28 controls. We characterized the immune landscape of dcLNs with scRNAseq and CITE-  
29 seq and observed increased memory B cell proportions and reduced germinal center  
30 (GC) B cells with decreased clonality in patients with MS compared to healthy controls.  
31 In the patient with an active MS relapse, we detected elevated plasmablasts, reduced  
32 GC B cells, and clonally expanded memory CD8 T cells targeting EBV in the dcLN.  
33 These findings, along with increased EBV DNA detection in dcLNs and viral loads in  
34 patient saliva, support B cell dysregulation as a key mechanism in MS pathogenesis.  
35  
36

## 37 INTRODUCTION

38 Multiple sclerosis (MS) is the most common neurological autoimmune disease affecting  
39 2.8 million individuals worldwide and has an increasing prevalence (1). Demyelinating  
40 inflammatory lesions of the central nervous system (CNS) are the cause of clinical  
41 attacks in relapsing-remitting MS (RRMS), which presents in 90% of patients, and  
42 migration of lymphocytes to the CNS is the hallmark of the disease pathology (2).  
43 Despite research efforts, the exact mechanisms that lead to MS remain unknown.

44  
45 Several environmental and genetic risk factors that predispose to MS have been  
46 observed, of which Epstein Barr Virus (EBV) infection in early adulthood is by far the  
47 most significant. EBV infection is characterized by the proliferation and transformation of  
48 infected B cells and the subsequent proliferation of CD8+ T cells targeting EBV. After  
49 primary infection, EBV persists lifelong in a small subset of B cells (3). Close to 100% of  
50 MS patients are EBV seropositive (4, 5), and recently, Bjornevik et al showed that EBV  
51 infection in early adulthood raises the risk for MS by 32-fold (6). These epidemiological  
52 findings were limited only to EBV, and seropositivity to other herpesviruses such as  
53 cytomegalovirus (CMV) does not raise the risk for MS.

54  
55 Antibodies recognizing EBV may cross-react with self-antigens (7). Recently, clonally  
56 expanded intrathecal plasmablasts (PBs) were found to produce antibodies that bind to  
57 EBV transcription factor EBNA1 but also to glial cell adhesion molecule (GlialCAM). In  
58 addition, EBNA1 immunization of experimental autoimmune encephalitis (EAE) mice  
59 exacerbated the EAE by increasing autoreactive B and T cell responses. (8) EBV-  
60 targeting cytotoxic CD8+ T cells have also been detected in autopsy samples of  
61 demyelinating brain lesions of MS patients. (9, 10)

62  
63 The adaptive immune response against EBV occurs most importantly in the deep  
64 cervical lymph nodes (dcLN) (11), which drain CNS lymphatics carrying neuronal  
65 autoantigens also in MS patients (12–14). Interestingly, dcLNs are enlarged in MS  
66 patients compared to healthy individuals (15), and clonally expanded B cells extracted  
67 from the demyelinating lesions in MS patients commonly derive from the dcLNs (16).

68 Therefore, it is plausible that dcLN could be the original site where MS pathogenesis is  
69 initiated.

70  
71 These findings, together with the high efficacy of B cell-depleting therapies in treating  
72 RRMS, have moved the MS research focus from T cells towards B cells and T-B cell  
73 crosstalk. B cell responses are refined in germinal centers (GCs), where B cell somatic  
74 hypermutations (SHMs) and class switching take place. GCs are typically found in  
75 secondary lymphoid tissues, such as LNs. Ectopic GCs, which develop in response to  
76 chronic inflammation (17), have also been found on the meninges of MS patients  
77 possibly contributing to B cell autoreactivity in MS (16, 18). The GC reaction is regulated  
78 by Tfr cells, whereas Tfh cells supply aid to developing B cells, which differentiate into  
79 memory B cells (MBCs) and high-affinity antibody (ab) producing PBs and plasma cells  
80 (PCs) (19). The ratio of follicular T helper cells (Tfh) to follicular regulator cells (Tfr) in  
81 the circulation has been reported to be increased in MS and to correlate with intrathecal  
82 IgG production, which suggests dysregulation of GC reactions (20).

83  
84 We hypothesized that EBV infection disrupts B cell homeostasis and the GC  
85 microenvironment in the dcLNs of MS patients, creating the ground for B cell-mediated  
86 autoimmunity. Using fine needle aspirations (FNAs) of the dcLNs (21) in newly  
87 diagnosed MS patients and healthy controls, we investigated the immunological  
88 landscape of dcLNs at single-cell resolution focusing on the GC reaction. We show, for  
89 the first time in an *ex vivo* analysis of MS patients, an intranodal expansion of memory B  
90 cells and diminished GC B cell proportion and clonality, paralleled by EBV detection.  
91 Our results reveal altered cellular composition of dcLNs in newly diagnosed MS  
92 patients, providing insights into the role of EBV in disease pathogenesis and to the  
93 efficacy of B cell depleting therapies in RRMS.

94

95

## 96 **RESULTS**

### 97 **Investigation of deep cervical lymph nodes accessed by fine needle aspirations**

98 Ultrasound-guided FNAs of dcLNs followed by isolation of viable single cells and  
99 immediate processing for 5' single-cell RNA sequencing including T and B cell receptor  
100 sequencing were performed on 7 MS patients (mean age 36 years, 4/9 females) and 6  
101 healthy controls (mean age 28 years, 3/5 females, Fig. 1A). The width and height of  
102 dcLNs, measured with ultrasound, did not differ between MS patients and controls  
103 (median 0.53 vs 0.49 cm, t-test  $p = 0.7024$ ; median 1.85 vs 1.26 cm, t-test  $p = 0.1673$ ,  
104 respectively). Hybrid-capture sequencing of DNA viruses (22) was performed on dcLN  
105 FNAs, and blood and saliva were collected for further viral assays. Clinical features of  
106 MS patients, including the Expanded Disability Status Scale (EDSS), are shown in  
107 Table 1, and further information on study subjects and assays is presented in Data file  
108 S1.

109  
110 After excluding samples with an abnormally low number of cells due to reported technical  
111 issues in 10x runs, scRNA-seq data from six MS patients and three healthy controls  
112 containing a total of 73,074 cells, with an average of 8,195 cells per MS patient and 7,968  
113 cells for the controls, were taken for further analysis. All cells were merged for combined  
114 cluster analysis in Seurat (23), and the resulting clusters contained cells from each  
115 sample without evident batch effect (Fig. 1B). We compared also cell clusters between  
116 the batches (Data file S1) and observed that resulting clusters were well aligned across  
117 library preparation and sequencing batches showing no specific batch effect (see  
118 Methods and Fig. S1A-E) (24). We performed cell type determination using a combination  
119 of automatic annotation with SingleR (25) using the Monaco reference (26) and manual  
120 annotation aided by the CITE-seq data that we had for 4/6 MS patients and all (3/3)  
121 healthy controls (Fig. 1C). Manual cell type determination was used especially for T and  
122 B cell subsets using a combination of key markers on both transcript and protein levels  
123 (Fig. 1D-E, Data file S2-3, see Supplementary Material for details). Most of the dcLN cells  
124 were either T or B cells, whereas natural killer (NK) cell and myeloid cell subsets  
125 accounted for less than 5% of all identified cells (Fig. 1F).

126

127 Two Tfh clusters were identified and characterized by canonical *CXCR5* expression (27),  
128 of which the other cluster was in the minority ( $\approx 0.5\%$  of all cells). Given the abundant  
129 expression of *BCL6* (28), *ICOS* (29), *TOX2* (30), *PDCD1* (31), *SH2D1A* (*SAP*) (32), and  
130 *IL21* (33), this smaller cluster likely represents a more active phenotype of Tfh (here GC  
131 Tfh) cells interacting with GC B cells (34) (Fig. 1D, Data file S2). Instead, the other Tfh  
132 cluster, which was the second most prevalent of all cells ( $\approx 11\%$ ) after naïve CD4+ T cells  
133 ( $\approx 40\%$ , Fig. 1F), could reside outside the GC given the lower *BCL6* expression (34, 35)  
134 and was annotated as Tfh-like cells (Fig. 1D).

### 135 **Increased proportion of memory B cells and decreased GC B cells and GC Tfh** 136 **cells in dcLNs of MS patients**

137 We noted a significantly increased proportion of memory and a marginally elevated  
138 proportion of naïve B cells in MS patients compared to healthy controls (unpaired t-test p  
139 = 0.042 and log2 fold change ( $\log_2\text{fc}$ ) = 0.88 for memory B cells; p = 0.064,  $\log_2\text{fc}$  = 0.75  
140 for naïve B cells, Fig. 1G, Data file S4). Next, we pooled all cells by subject group and  
141 compared the overall cell type frequency distribution between MS patients and healthy  
142 controls. The cell type frequencies, representing cellular compositions in dcLNs, were  
143 significantly different between MS patients and controls (Pearson's Chi-squared test, p-  
144 value < 2.2e-16). Furthermore, evaluation of the standardized Pearson residuals  
145 suggests that in addition to memory and naïve B cells, PBs and Tfh-like cells were  
146 significantly increased while naïve and intermediate CD4s, GC B cells, naïve CD8s, and  
147 GC Tfh cells were significantly decreased in MS patients compared to healthy controls  
148 (Fig. 1H, each having extreme standardized Pearson residual values above  $\pm 3.65$ ,  
149 corresponding to Bonferroni corrected p-values < 0.00013 in the null distribution of the  
150 standardized residuals). Tfr cells, which share transcriptional properties with Treg and Tfh  
151 cells and differentially expressed *FOXP3*, *IKZF2*, *CTLA4* on transcript level and *PDCD1*,  
152 and *ICOS* on both transcript and protein level (19, 36) (Data file S2-3), did not differ  
153 between MS patients and healthy controls. Decreased GC B cells and GC Tfh cells  
154 combined with a simultaneous expansion of memory B cells suggest an imbalance of the  
155 GC reaction in MS.

156

157 We also conducted differential expression (DE) analysis for pseudobulked cell types. The  
158 highest number of DE genes (DEG) in MS samples compared to controls were observed  
159 in naïve CD4 T cells followed by plasmablasts, NK cells, and GC B cells (Fig. S1F, Data  
160 file S5). In MS patients, plasmablasts upregulated several immunoglobulin (IG) heavy and  
161 light chain genes compared to healthy controls. GC B cells upregulated *CCDN2* (*cyclin*  
162 *D2*,  $P_{\text{adj}} = 0.024$ ,  $\log_2\text{fc} = 1.97$ ) and downregulated *LYN* ( $P_{\text{adj}} = 0.024$ ,  $\log_2\text{fc} = 0.93$ ) in  
163 the MS group as compared to controls. *CCDN2* is upregulated during positive selection  
164 in GCs (37), whereas loss of *Lyn* has been linked with a lupus-like autoimmune disease  
165 with hyperactive B cells (38). Although statistically not significant, the expression of  
166 canonical B cell marker *CD19*, known to regulate B cell proliferation in GC reaction (39),  
167 was decreased in GC B cells of MS patients ( $P_{\text{adj}} = 0.07$ ,  $\log_2\text{fc} = -1.12$ ) in transcription  
168 level, and also in protein level ( $P_{\text{adj}} = 5.9\text{e-}18$ ,  $\log_2\text{fc} = -0.47$ ) together with *CR1* ( $P_{\text{adj}} =$   
169  $6.7\text{e-}12$ ,  $\log_2\text{fc} = -0.47$ ) and *CR2* ( $P_{\text{adj}} = 1.4\text{e-}17$ ,  $\log_2\text{fc} = -0.55$ ) (Fig. S1G). Interestingly,  
170 the *CR1* and *CR2* expression on B cells is also decreased in systemic lupus  
171 erythematosus and rheumatoid arthritis (40). Memory CD8+ T cells were upregulating an  
172 IFN $\gamma$  modulator *DKK3* (*Dickkopf-3*,  $P_{\text{adj}} = 0.0015$ ,  $\log_2\text{fc} 2.12$ ), *TIGIT* ( $P_{\text{adj}} = 0.038$ ,  $\log_2\text{fc}$   
173  $= 0.59$ ), and cytotoxic granzymes A and K in MS patients compared to controls (*GZMA*,  
174  $P_{\text{adj}} = 0.038$ ,  $\log_2\text{fc} = 0.44$ ; *GZMB*,  $P_{\text{adj}} = 0.0028$ ,  $\log_2\text{fc} = 0.50$ ). *DKK3* is upregulated in  
175 EAE (41) and *TIGIT* has been shown to promote CD8+ T cell exhaustion (42).

176

### 177 **Double-negative memory B cells are increased in MS patients**

178 To further characterize the B cell compartment where we found most differences in  
179 abundance, we sub-clustered B cells. We identified similar B cell subsets as presented in  
180 Fig. 1C, in addition to a T cell cluster initially clustered with memory and naïve B cells due  
181 to a similar expression profile (Fig. S2A, Data file S6). The proportion of naïve B cells was  
182 increased in MS dcLNs after removing the remaining T cells ( $p = 0.035$  and  $\log_2\text{fc} = 0.82$ ,  
183 Fig. S2B, Data file S7). Then we sub-clustered the memory and naïve B cells presented  
184 in Fig. S2A and identified clusters of CD27 positive and IgD negative switched memory  
185 (SM), CD27 and IgD positive unswitched memory (USM), and CD27 and IgD low double

186 negative (DN) B cells in addition to naïve B cells with the combination of both transcript  
187 and protein level information (Fig. 2A-B, Fig. S2C, Data file S8). MS patients had elevated  
188 proportions of the USM, SM, and naïve B cells, yet only the proportion of DN B cells was  
189 significantly larger (% of B cells,  $p = 0.041$  and  $\log_2\text{fc} = 1.82$ , Fig. 2C; % of all cells,  $p =$   
190  $0.048$  and  $\log_2\text{fc} = 2.51$ , Fig. S2D, Data file S9). Of note, DN B cells expressed less  
191 CXCR5 than SM and USM B cells at both RNA and protein levels (Fig. 2B, Fig. S2C),  
192 indicating that DN B cells could have been derived extrafollicularly (43, 44). Despite being  
193 limited by cell numbers from dcLNs, in a subset of samples with higher cell yields, we  
194 also performed flow cytometry analysis of the B cell compartment (see Methods, Fig.  
195 S2E). We adapted the gating strategy from (45) and observed that the proportion of GC  
196 B cells (CD19+CD20+CD38++CD10+IgD-) was reduced in MS patients compared to  
197 controls and the proportions of memory (CD19+CD20+CD27+) and naïve  
198 (CD19+CD20+IgD+CD27-CD38-) B cells were increased, however, due to the small  
199 sample size, these results did not reach statistical significance (Fig. S2F). Moreover,  
200 when dissecting the memory B cell compartment, the proportions of SM  
201 (CD19+CD20+CD27+IgD-IgM-CD38-) and DN (CD19+CD20+CD27-IgD-IgM-CD38-) B  
202 cells were higher in MS patients, however again without statistically significant difference  
203 to healthy controls (Fig S2F). The flow cytometry results align with our findings from the  
204 scRNAseq/CITEseq data, corroborating our observations of a larger memory B cell  
205 compartment together with fewer GC B cells in the dcLNs of MS patients.

206  
207 Next, we sub-clustered the GC B cells to study the GC reaction more thoroughly. We  
208 identified *CD83* and *BCL2A1* expressing light zone (LZ) B cells (46, 47), *CXCR4*, *AICDA*,  
209 and *MKI67* expressing dark zone (DZ1, DZ2) B cells (46, 47), and an unidentified GC B  
210 cluster (GC.B) characterized with *MS4A1/CD20* and *MKI67* and negligible *CD3*  
211 expression (Fig. 2D-F, Data file S10). Active proliferation is a defining characteristic of  
212 GC B cells, and that is why no cell-cycle correction was performed and explains why the  
213 sub-clustering of GC B cells also contained a small cluster of proliferative T cells (Fig.  
214 2G). Supporting the imbalanced GC reaction, we noticed that within the B cell  
215 compartment, the proportion of GC B cell subsets of all B cells showed a lower trend in  
216 MS patients (Fig. S2G). Within GC B cells, the GC.B cluster was significantly increased



217 in MS dcLNs compared to healthy controls ( $p = 0.011$  and  $\log_2fc = 2.42$ , Fig. 2G, Data  
218 file S11). As expected, pathway analysis of cluster-defining DEGs ( $P_{adj} < 0.05$ ) with GO  
219 biological processes showed a significant over-representation of pathways related to B  
220 cell activation and differentiation among upregulated genes of LZ B cells and replication  
221 among those of DZ B cells. Interestingly, the GC.B cluster, which was increased in MS  
222 patients, showed an over-representation of ribosomal genes related to viral transcription  
223 and viral gene expression (Data file S1).

224

### 225 **Cellular interactions between follicular T cells and GC B cells**

226 Since MS patients had an increased proportion of naïve B cells, memory B cells, and  
227 PBs, while GC B cell and GC Tfh proportions were decreased compared to healthy  
228 controls, we hypothesized that the interaction between T and B cell subsets is altered.  
229 To study intercellular interactions, we used NicheNet (48), which links transcripts of  
230 ligands in sender cells to their transcript targets in the receiver cell. Principally  
231 developing GC B cells rely on signals from Tfh via CD40 – CD40L interaction to  
232 undergo SHM and class-switching (49). Similarly, the most active CD40 – CD40LG  
233 interactions for GC B cells were predicted between GC Tfh and Tfh-like cells (Fig. 3A).  
234 Integrins prolong interactions between T and B cells (50), and interestingly *CD40LG* –  
235 *ITGB1* (integrin beta 1) interaction was observed only between GC Tfh and GC B cells  
236 emphasizing their crosstalk in GCs. GC Tfh cells were the only CD4+ T cells which  
237 interacted with GC B cells via *CD28* – *CD86* and *CD28* – *CD80*, of which the latter is  
238 reported to be crucial for T-B interactions in GC responses (51). Contrary to our  
239 hypothesis, the above interactions between GC B cells and Tfh cells were similar for MS  
240 patients and controls when compared using MultiNicheNet (52) (Fig. S3A). We  
241 observed a slight increase in *galactin-1 (LGALS1)* – *lectin receptor CD69* interaction  
242 between GC B and Tfh cells in MS patients (Fig. S3A), of which galactin-1 is shown to  
243 favour PB differentiation (53). We did not observe *IL21* – *IL21R* interaction between GC  
244 B cells and GC Tfh cells, however, this could have been affected by the small  
245 proportions of both cell subsets. Instead, *IL21* – *IL21R* interaction was increased  
246 between GC Tfh and naïve B cells, suggesting that part of the naïve B cells could have

247 already been dedicated for the GC reaction (33) (Fig. 3A). In line with this, *CD40LG* –  
248 *CD40* interaction between GC Tfh/Tfh-like cells and naïve B cells was decreased in MS  
249 patients compared to GC B cells (Fig. S3A). The naïve B cells dedicated to the GC  
250 reaction could potentially receive less necessary proliferative signals from Tfh cells in  
251 MS patients, which could lead to an altered GC response.

252

253 The precise mechanisms of how Tfr cells control the GC reaction and selection of Tfh  
254 and GC B cell clones are largely unknown. Here, Tfr cells were predicted to interact with  
255 GC B cells via *CD28* – *CD80/CD86* (Fig. 3A), which is needed for Tfr differentiation  
256 (54). We did not observe CTLA4-mediated inhibition of CD80/CD86 costimulatory  
257 signals between Tfr and GC B cells, which has been thought to play a key role in the  
258 regulation of GC reaction (55). B cell proliferation, memory responses, and CXCR5  
259 expression of GC B cells are downregulated via HLA-G – *LILRB1* (also known as *ILT2*)  
260 interaction between T and B cells (56). *B2M* (beta-2-microglobulin) constitutes the light  
261 chain of HLA-G, and *B2M* – *LILRB1* interaction was predicted only between Tfr and GC  
262 B cells (Fig. 3A). Possibly *B2M* – *LILRB1* interaction is one mechanism for Tfr cells to  
263 regulate GC B cell development and thus, GC reaction.

264

### 265 **GC B cells are less clonal in dcLNs of MS patients**

266 We evaluated the BCR repertoire in dcLNs of MS patients and healthy controls. On  
267 average, BCRs from 1400 cells per MS patient and 882 per healthy control sample were  
268 obtained. We observed no difference in the diversity of the total BCR repertoire (Fig. 3B),  
269 nor in the BCR diversity of naïve B cells, memory B cells, or plasmablasts between  
270 patients and controls (Fig. S3B). However, the BCR diversity of GC B cells was  
271 significantly higher in MS patients when compared to healthy controls (Fig. 3C). To  
272 confirm this, we used the Lanz et al. (8) definition for BCR clonotypes (see Methods)  
273 where we still observed significantly increased diversity only in the GC B cell compartment  
274 of MS patients (Fig. S3C). In summary, while we could detect a lower proportion of GC B  
275 cells in MS dcLNs (Fig. 1H), their standardized BCR diversity was higher than in healthy  
276 controls.

277

## 278 **TCR repertoire in dcLNs is similar between MS patients and controls**

279 From T cells we obtained single-cell paired TCR $\alpha\beta$  data for an average of 6124 cells  
280 per MS patient and 6702 for healthy control, corresponding to 5851 and 6384 average  
281 unique TCR clonotypes, respectively (Fig. S3D). Comparison of TCR diversity in the  
282 entire dcLN-paired-TCR $\alpha\beta$  repertoire, with and without downsampling to the same read-  
283 depth, showed no statistical difference in TCR clonality between MS and healthy  
284 controls (Fig. 3D). We also found no statistical difference in repertoire diversity within  
285 specific T cell subpopulations between patients and controls (Fig. S3E). To determine  
286 the possibility of more TCR sharing among MS patients, we also compared TCR amino  
287 acid level overlap rates for every possible pair between patients and controls, however,  
288 no evidence for increased TCR overlap in MS dcLNs was found (Fig. S3F).

289

290 Given the decreased GC B cell clonality and proportion in MS dcLNs, we examined  
291 follicular T cells closer. Only a few TCRs of Tfh-like, GC Tfh, and Tfr cells were shared  
292 with TCRs from other T cell subsets within each individual, with no difference between  
293 MS patients and controls (Fig. S3G). Tfr cells shared TCR clones with both Treg (in 3/6  
294 MS patients and 1/3 controls) and Tfh-like cells (in 1/6 MS patients and 1/3 controls),  
295 indicating that Tfr cells had developed from both cell types. A trajectory analysis of the  
296 scRNA-seq data from Tfh-like, GC Tfh, Tfr, and Treg cells using slingshot (57) showed  
297 a single developmental trajectory encompassing from Tfh-like cells via GC Tfh and Tfr  
298 to Treg cells, suggesting that Tfr cells had developed from both Tfh and Treg cells, in  
299 line with recent findings (Fig. S3H) (58).

300

301 To compare the antigen-driven TCR repertoire in the patients' dcLNs to controls, we  
302 scanned the VDJdb database for possible specificity of all our TCR $\alpha\beta$  amino acid  
303 clonotypes using tcrdist3 (see Methods). Predicted T-cell-specificity was higher in MS  
304 patients towards epitopes of *M.tuberculosis* in Naïve CD4s (p-value=0.03, log<sub>2</sub>fc = 0.5),  
305 Influenza A (p-value = 0.003, log<sub>2</sub>fc = 3) and EBV (marginally with p-value = 0.08 & log<sub>2</sub>fc  
306 = 0.56) in GC Tfh cells (Fig. S3I), however, these were insignificant after we filtered for

307 HLA restriction of target TCRs (retaining HLA class 2 restricted hits for CD4+ T cells, and  
308 HLA class 1 restricted hits for CD8+ T cells).

309

### 310 **Higher coverages of EBV, HHV-6B and HHV-7 in dcLNs and viral loads of EBV in** 311 **the saliva of MS patients**

312 All MS patients were seropositive for EBV viral capsid antigen (VCA) IgG (9/9), whereas  
313 only five of the six controls were EBV VCA IgG seropositive. Of the EBV VCA IgG  
314 seropositive individuals, MS patients had higher EBV VCA IgG titer than healthy controls  
315 ( $p = 0.019$ , Fig. S4A). None of the subjects were seropositive for EBV VCA IgM.

316

317 Next, by using hybrid-capture sequencing, we searched for common human DNA viruses  
318 from fine needle aspirations of dcLNs ( $n_{MS}=4$ ,  $n_{hc}=4$ , Fig. 1A). The prevalence of EBV  
319 (75% vs 50%, human-herpesvirus-6B (HHV-6B, 50% vs 0%), and HHV-7 (100% vs 75%),  
320 but also the total number of unique viral reads covering the reference sequences, which  
321 correlates to the viral copy numbers (59), was higher in MS patients compared to controls  
322 (Fig. 4A, Table 2). The coverages of HHV-7 were particularly higher in MS patients, from  
323 whom we were able to reconstruct two near-complete viral genomes. Three out of four  
324 MS patients were positive for parvovirus B19 (B19V) compared to 100% of controls. Equal  
325 prevalence (50%) of Merkel cell polyomavirus was detected in both MS patients and  
326 healthy controls. Importantly, MS patients and healthy controls clustered into separate  
327 clusters based on the breadth coverage profiles of the above-tested viruses (Fig. 4A). We  
328 aligned the scRNA-seq data to reference viral genomes available at ViruSITE (60) and  
329 NCBI (61) databases (see Methods) including EBV genome to identify cells producing  
330 viral transcripts (62). However, we did not find any cells producing transcripts of EBV, or  
331 other herpesviruses.

332

333 Using multiplex qPCR HERQ-9 quantification we searched for EBV DNA from the saliva  
334 as a sign of EBV reactivation. We found three out of nine HHVs in the saliva of MS patients  
335 and controls: EBV, HHV-6B, and HHV-7. Herpes simplex virus-1 (HSV-1), HSV-2,  
336 varicella-zoster virus, CMV, HHV-6A or Kaposi's sarcoma-associated herpesvirus were

337 not detected in any of the samples. EBV was found from saliva in all except one of the  
338 MS patients in contrast to only one of the controls, and the viral loads in MS patients were  
339 significantly higher ( $p = 0.011$ ) (Fig. 4B). Surprisingly, the MS patient negative for EBV  
340 DNA in dcLN had the highest EBV viral load in saliva. HHV-6B was found in most samples  
341 and HHV-7 in all without significant differences in the viral loads for either of these viruses  
342 between groups (Fig. S4B).

343

#### 344 **Patient with an active MS relapse exhibits EBV targeting memory CD8 cells,** 345 **skewed follicular T cell ratios, and negligible GC B cells**

346 Immunological processes during active MS relapse are poorly understood, partly  
347 because treatment is usually started soon after hospital admission. We managed to  
348 obtain dcLN FNA from one patient during hospitalisation for an active MS relapse before  
349 immunomodulatory treatments were started. The patient (MS011) had no other known  
350 diseases besides MS nor an immediate history of infections and exhibited weakness of  
351 the right leg and diplopia with EDSS of 3.5 in the clinical evaluation during the relapse  
352 (Table 1). The patient's plasma EBV VCA IgG concentration and copy numbers of  
353 HHVs in saliva were comparable to MS patients (Table 2).

354

355 When comparing cell abundancies from dcLNs, we observed that the patient had the  
356 highest proportions of PBs, Tfh-like, and memory CD8 T cells, and the lowest  
357 proportions of naïve, intermediate, and effector CD4, GC Tfh, Tfr, and GC B cells  
358 across all subjects (Fig. 1G, Fig. S5A). The abundance of memory and naïve B cells  
359 were similar to those in other patients. The ratio of GC Tfh to Tfh-like cells was reduced,  
360 while the total Tfh to Tfr ratio was significantly increased (Fig. 5A), both likely due to the  
361 drastic increase of Tfh-like cells (Fig. S5A). Moreover, the patient had the lowest  
362 proportion of DZ and LZ B cells of all B cells. Within the GC B cell compartment the  
363 cluster of GC.B cells, characterized by upregulation of transcripts involved in pathways  
364 of viral transcription and viral gene expression, was significantly increased (Fig. 2G,  
365 S2D, S5B).

366

367 We also redid analysis on cellular abundancies between patients and controls after  
368 excluding the patient with acute exacerbation to evaluate how much of the results were  
369 affected by the acute case. After excluding the acute relapse patient, non-treated MS  
370 patients still had significantly increased memory and naïve B, and effector CD4 T cells,  
371 decreased GC B, naïve CD4, and CD8, and intermediate CD4 T cells, and marginally  
372 decreased GC Tfh cells (Fig. 5B). To conclude, the alterations of lymphocytes  
373 characterized with larger memory B cell compartment and smaller proportion of GC B  
374 cells in dcLNs seem more pronounced in early MS during a relapse.

375  
376 The patient had the highest number of all BCRs and PB BCRs (Fig. 5C), whereas the  
377 lowest of GC B cell BCRs (5 GC B cell BCRs of 1758 detected BCRs, detected BCRs in  
378 all samples ranged from 599 to 1758). On the TCR side, while the relative frequency of  
379 expanded T-cell clonotypes was not statistically different between the patient groups,  
380 the largest percent of cells from expanded TCR clonotypes was seen in the patient with  
381 relapse (1.16% of all T cell clonotypes were expanded, the median in MS patients is  
382 0.40% and in controls 0.15%; paired TCR clonotypes with frequencies of over 0.001 of  
383 all clonotypes within each sample were considered expanded), of which the most (84%)  
384 were memory CD8 T cells (Fig. 5D). Notably, the majority of the clonally expanded T  
385 cells from the patient were predicted to be EBV specific, whereas no EBV specific TCRs  
386 were seen in T cells of other subjects (Fig. 5E). We validated and refined the TCR  
387 predictions with an orthogonal method TCRGP, which has outperformed the original  
388 tcrdist algorithm (63). With TCRGP, we confirmed the enrichment of clonally expanded  
389 CD8+ TCR specific to EBV antigen EBNA3B in the patient with an active relapse (Fig.  
390 S5C,  $P_{\text{adj}} = 0.0002$ , odds ratio (OR) = 18.80, Benjamini-Hochberg corrected one-sided  
391 Fisher's exact test).

## 392 **DISCUSSION**

393 Therapeutic advances during the last decades have highlighted the role of B cells and  
394 T-B crosstalk in MS pathogenesis. Examining B cell subsets at the site where B cell-  
395 mediated immunity evolves is essential for gaining a deeper understanding of the origin  
396 of MS and for elucidating why systemic B cell-depletion effectively treats the disease.  
397 Here, to the best of our knowledge, we have provided the first-ever characterization of  
398 the single-cell immune landscape in the dcLNs of newly diagnosed MS patients by  
399 coupling scRNA-seq with CITE-seq. The B cell compartment of dcLNs is altered in MS  
400 patients with an increase in memory B cells and decreased GC B cells with reduced  
401 clonality suggesting a disturbance of GC reactions. Hybrid-capture sequencing of  
402 eukaryotic DNA virome detected EBV, HHV-6B and HHV-7 DNA more readily in the  
403 patients' dcLNs than the controls. Moreover, using multiplex qPCR from the saliva  
404 against common herpesviruses, EBV DNA was witnessed primarily in the patients and  
405 not the controls. In addition, the MS patient sampled during an acute relapse presented  
406 with starker findings in the same B cell subsets together with clonally expanded memory  
407 CD8<sup>+</sup> T cells whose TCRs were likely targeting EBV.

408  
409 Expansion of memory B cells and plasma cells in the CSF of MS patients is well  
410 demonstrated (8, 16, 64). Simultaneously, Tfh cells are more prevalent both in CSF of  
411 MS patients and in MS animal models, where Tfh cells promote B cell accumulation and  
412 disease progression (64). Therapeutic effect of systemic B cell depletion is mirrored in  
413 CSF by a decrease in memory B cells, which further underlines the role of B cell  
414 dysregulation in MS. Based on studies with twins (65) or with paired CSF and blood  
415 samples (64, 66) the B cell expansion is restricted to the CNS, whereas peripheral  
416 blood reflects the B cell compartment inadequately. Even though the expanded memory  
417 B cells are shown to derive from the dcLNs (16), the role of dcLNs in MS has been  
418 largely unstudied. To enlighten this, we investigated the dcLNs in MS patients and  
419 controls and discovered that the proportion of memory B cells and to a smaller degree  
420 PBs was augmented in dcLNs of MS patients. This suggests that the reported  
421 expansion of intrathecal B cells, plasma cells (64) and circulatory memory B cells in  
422 early MS (67) derive from alterations of B cell maturation in the dcLNs. In addition, MS

423 patients had fewer and less clonal GC B cells further suggesting dysregulation in GC  
424 reaction. Also, the Tfh cells likely representing GC-resident Tfh cells (34) interacting  
425 with GC B cells due to expression of *BCL6* (28), *ICOS* (29), *TOX2* (30), *PDCD1* (31),  
426 *SH2D1A* (*SAP*) (32) were decreased in MS patients. Tentatively, GC B cells could  
427 receive less survival signals in the light zone from GC-resident Tfh cells leading to  
428 favoring the B cell differentiation toward memory B cell fate over PB fate (49, 68) and to  
429 GC contraction (69) in dcLNs of MS patients. This would subsequently explain the  
430 decrease of GC B cells in MS patients. Interestingly, autoimmunity-linked DN (45) but  
431 also switched-memory B cells were increased in MS patients. Both of them could  
432 develop in extrafollicular responses of the lymph node, not only in GCs (43). On the  
433 other hand, Tfh cell-proportions were skewed especially in the patient with a relapse, in  
434 which Tfh-like cells, that probably remain outside the GC (GC-nonresident Tfh), were  
435 expanded. Chronic viral infections seem to favour Tfh differentiation, yet result in  
436 dysregulated Tfh – GC B cell interactions (79). Hence, local activation of latent EBV  
437 could be a driver for the GC-nonresident Tfh expansion during the disease relapses  
438 leading to a larger memory B cell compartment in MS patients as observed here.  
439 Further studies on larger datasets with paired CSF samples are warranted to  
440 demonstrate whether altered GC reaction in dcLNs is the origin of clonally expanded  
441 intrathecal B cells in MS, potentially opening the door to new therapeutic strategies.  
442  
443 Epidemiological evidence for EBV infection as a prerequisite for MS onset is strong.  
444 However, the exact pathogenic mechanisms leading to MS after this ubiquitous viral  
445 infection are still unresolved. Molecular mimicry between CNS structures and EBV has  
446 been widely acknowledged (8), but why such reactions lead to CNS autoimmunity in  
447 only a minority of humans infected with EBV remains still unresolved. Findings of EBV  
448 from postmortem samples have been contradicting (70–72), thus an uncontrolled viral  
449 activation or replication as the cause of MS is still debatable. Interestingly, spontaneous  
450 proliferation of CD4+ T cells initiated by memory B cells has been reported in MS  
451 patients with HLA-DR15 haplotype (73) and is stimulated by EBV peptides (74).  
452 Considering the observed expansion of memory B cells in MS dcLNs, EBV-infected B  
453 cells could be the source of uncontrolled proliferation of CD4+ T cells.



454

455 Contrary to previous results by Gieß et al (75), we observed EBV DNA in the saliva of  
456 adult early MS patients, possibly due to a more sensitive method. Similarly, oral  
457 shedding of EBV as a possible sign of EBV lytic cycle reactivation has been reported in  
458 pediatric MS patients (76). We detected EBV DNA in higher prevalence in MS patients  
459 dcLNs than in controls, however, we could not find cells producing EBV nor other  
460 aforementioned viruses by aligning scRNA-seq reads to viral genomes. Yet, it should be  
461 noted that the copies of the viruses detected by hybrid-capture sequencing were likely  
462 to be few, and the low efficiency of scRNA-seq library preparation (77) limits the  
463 likelihood of detecting cells with viral transcripts from the scRNA-seq data. Our findings  
464 of EBV activation lead us to speculate whether, in early MS, relapses could rise from  
465 local activation of latent EBV in dcLNs, which would not be detected systematically with  
466 serological assays (78). Recently, EBV-specific memory CD8<sup>+</sup> T cells were observed in  
467 CSF of both healthy controls and MS patients, however, patients' had also central  
468 memory CD8<sup>+</sup> T cells associated with broader EBV-specific repertoires (80). In our  
469 study, the patient with an ongoing relapse had expanded EBV targeting memory CD8<sup>+</sup>  
470 T cells, and it is possible that they expand and migrate to CNS during a relapse, since  
471 this was not observed in patients without active relapses.

472

473 The understanding of GC reaction is largely based on experiments with mice, and  
474 studies with human tissues, especially in autoimmunity are few since patient recruitment  
475 and sample collection are challenging. Our dcLN data set from recently diagnosed MS  
476 patients without immunosuppressive medication is unique, however, it is restricted with  
477 the small sample size. Also, our scRNAseq experiments were limited to 10,000 cells per  
478 sample, which impeded the T and B cell clonotype analysis. The majority of the VDJdb  
479 database is based on CD8<sup>+</sup> T cells, which could explain why we could not detect CD4<sup>+</sup>  
480 T cell subsets targeting several viruses, such as EBV. Despite the limited cell number  
481 per sample, we studied paired TCRαβ data from an average of 6124 T cells per MS  
482 patient and 6702 per healthy control, which increases the specificity of our clonotype  
483 results. Yet, we did not find any differences in repertoire diversity within specific T-cell  
484 subpopulations when comparing MS patients to healthy controls, which suggests that

485 clonal expansion of specific T cell clones unlikely dominates in dcLNs outside the MS  
486 relapses. The only EBV-targeting T cells were clonally expanded memory CD8+ T cells  
487 found only in the MS patient with a relapse. Using TCRGP, we confirmed that the  
488 memory CD8+ TCRs in the patient with relapse were specific to latency-associated EBV  
489 antigen EBNA3B (7) and increased 18.8 times compared to healthy controls.

490  
491 Our results encourage the use of FNA and scRNAseq to study lymphoid tissues,  
492 including ectopic GCs in autoimmune infiltrates, in various diseases to better  
493 understand autoimmune mechanisms and development of memory B cells and  
494 plasmablasts. By investigating the single-cell immune microenvironment of dcLNs at the  
495 diagnosis of MS, we observe increased memory B cell compartment along with  
496 decreased GC B cells in comparison to healthy controls, suggesting malfunction of the  
497 GC reaction in the patients. Paralleled with findings related to EBV and the known  
498 influence of EBV on GC dynamics (81), our results support B cell dysregulation as a key  
499 mechanism in MS pathogenesis.

500

## 501 **MATERIALS AND METHODS**

### 502 **Study design**

503 We studied the cellular compartment of dcLNs in MS patients and healthy controls using  
504 ultrasound-guided FNAs. Viable single cells were isolated from the FNAs and  
505 subsequently processed for 5' single-cell RNA sequencing and hybrid-capture  
506 sequencing of DNA viruses (22). Also, blood and saliva were collected from the  
507 participants for additional viral assays.

508  
509 This study was approved by the Helsinki University Hospital ethical committee (decision  
510 number 5774/2020; research permit number 2363/2020). All subjects participated  
511 voluntarily and gave written informed consent according to the principles of the  
512 Declaration of Helsinki. Nine newly diagnosed MS patients and 7 age and sex-matched  
513 healthy controls were selected for this study between April 2021 and March 2022. MS  
514 diagnosis was confirmed by an experienced neurologist at the Helsinki University  
515 Hospital using the 2017 McDonald diagnostic criteria (82, 83). The full diagnostic  
516 workup included evaluation by a neuroimmunologist, CSF analysis, and a head MRI. All  
517 MS patients had oligoclonal bands in CSF at the time of diagnosis. We only chose MS  
518 patients without any immunomodulatory medications. In addition, an absence of  
519 intravenous glucocorticoid infusion within 3 months before sample collection was a part  
520 of the inclusion criteria. Further patient characteristics are shown in Data file S1.

521

### 522 **Sampling of blood and saliva**

523 Blood and saliva were taken 1 to 3 hours before the FNA sample. Blood samples were  
524 collected into Li-heparin Vacutainer tubes (BD Biosciences), and plasma was separated  
525 by centrifugation and archived at -80 C° until enzyme-linked immunosorbent assay  
526 (ELISA). Subjects had a minimum of a 30-minute break from any liquids or solid foods  
527 before saliva samples were obtained. The samples were collected at noon to normalize  
528 the diurnal variation of protein secretion and stored at -20 C°. EBV serology status was

529 evaluated using Anti-EBV-CA ELISA IgG and IgM kits (Euroimmun, CAT#: EI 2791-  
530 9601 G, EI 2791-9601 M) according to the manufacturer's instructions.

### 531 **Fine needle aspirations**

532 Ultrasound-guided FNAs of dcLNs and subsequent processing for single-cell  
533 sequencing were performed as described previously by Turner et al (84). Briefly,  
534 radiologists (G.K, R.L) first measured dcLNs (Table 1), after which they performed  
535 FNAs under visualization with a 25-gauge needle. For each sample, 2 aspirations were  
536 taken and collected into 3ml of 10% FBS in RPMI 1640 followed by three 0.5 ml rinses.  
537 After one wash with 2% FBS and 0.5mM EDTA in PBS, red blood cells were eliminated  
538 using 1ml of ACK lysis (Lonza) followed by another wash using PBS supplemented with  
539 2% FBS and 0.5mM EDTA. Single-cell RNA sequencing was performed in  
540 concentrations of  $1 \times 10^7$  cells per ml in calcium- and magnesium-free PBS with 0.04%  
541 BSA solely or in parallel with the cellular indexing of transcriptomes and epitopes by  
542 sequencing (CITE-seq). CITE-seq staining was performed for a minimum of 500,000  
543 cells using TotalSeq™-C Human Universal Cocktail (BioLegend, cat 399905) according  
544 to the manual. For the samples in which solely scRNAseq was performed, 10,000 cells  
545 were targeted for sequencing. For part of the samples (Data file S1), a flow cytometry  
546 assay was also performed to characterize B cell subsets (described further). The  
547 remaining cells were frozen in RNA Later (Thermo Fisher) according to the  
548 manufacturer's instructions at  $-80\text{ C}^\circ$ .

549

### 550 **Single-cell sequencing**

551 scRNAseq was performed for 7/9 MS and 5/7 healthy control dcLN FNA samples of  
552 which CITE-seq was performed for 5 MS and all healthy control samples. FIMM Single-  
553 Cell Analytics core center at the University of Helsinki performed 5'RNAseq run and  
554 library preparation for scRNAseq, TCR $\alpha\beta$ , and BCR libraries using the Chromium Single  
555 Cell 5' (v2 Chemistry Dual Index) with Feature Barcoding technology for Cell Surface  
556 Protein and Immune Receptor Mapping (CITE-seq) as instructed by the manufacturer  
557 (10X Genomics).

558

559 The sequencing was started immediately after FNA sample preparation and libraries  
560 were sequenced on Illumina NovaSeq 6000 system (read lengths 26bp (Read 1), 10bp  
561 (i7 Index), 10bp (i5 Index), and 90bp (Read 2). The raw scRNAseq data were  
562 processed using Cell Ranger (v 2.2.0) against the human genome GRCh38. TCR $\alpha\beta$   
563 and BCR data were processed with Cell Ranger vdj pipeline to generate single cell  
564 V(D)J sequences and paired clonotype calling according to the manufacturer's  
565 instructions.

566

### 567 **Single-cell RNA, CITE-seq, and scTCR & BCR data analysis**

568 Analysis of scRNAseq data was performed using Seurat (v4.1.1) in R (23). Initial QC was  
569 performed separately for each sample in which cells in the top 2 percentile for  
570 mitochondrial gene expression and in the top 1 percentile for the number of genes  
571 detected were removed. Also, one MS sample and three healthy control samples with an  
572 abnormally low number of cells due to technical issues in 10x runs were removed. The  
573 remaining samples were combined for cluster analysis with the merge function in Seurat.  
574 Uniform manifold approximation and projection (UMAP) was then performed in Seurat  
575 using the top 50 principal components of the merged data. Graph-based clustering and  
576 cluster labelling were performed with a resolution of 1 of the FindClusters function. The  
577 resulting clusters were defined by cell types and were well mixed from all possible batches  
578 (library and sequencing batches, Fig. S1A-D). In addition, no sample or patient group-  
579 specific misalignment of cell clusters was observed (Fig. 1B, Fig. S1E), thus no batch  
580 correction of the dataset was needed. Cell-level cell-type annotation was mainly  
581 performed with the reference-based SingleR method (v1.10.0) (25) using the Monaco  
582 immune data as a reference (26). The most frequent cell-level annotation was assigned  
583 to each cluster, and cell clusters with the same annotation were readily combined. We  
584 then confirmed and refined the cluster-level annotations manually using cluster markers  
585 detected from the scRNA-seq and CITE-seq data (Fig. 1D-E) and annotated additional  
586 cell types of interest (such as GC B cells, Tfh-like, GC Tfh, Tfr) that were missing in the  
587 reference data for SingleR. We also performed sub-clustering of B cell subsets, for which

588 cluster annotations were performed manually based on cluster markers detected from the  
589 scRNA-seq and CITE-seq data (Fig. 2, Data file S6,8,10).

590  
591 We then used the cell clusters as defined by the annotation above for further analyses.  
592 To identify differentially abundant cell types in MS, cell type composition was evaluated  
593 between MS and control samples by comparing the proportion of the cell types in the two  
594 conditions. Differential gene expression was identified for each cell type using the  
595 pseudobulk approach, which has been reported to outperform other single-cell DE  
596 methods (85), by sum aggregating the RNA counts of genes per cell type per sample,  
597 and comparing the pseudobulk gene expression within each cell type between MS and  
598 controls using DESeq2 (v1.36.0) (86). Biological pathway analysis was then performed  
599 for each cell type using the pathway-express method (R package ROntoTools v2.24.0)  
600 (87, 88).

601  
602 Basic evaluation and comparison of immune single-cell level TCR and BCR repertoire  
603 clonality/diversity and clonal overlap were done with scRepertoire (v1.6.0) (89) and in-  
604 house custom R script. We scanned the VDJdb database (release 2022-03-30) (90) of  
605 known TCR-epitope targets for possible specificity of our TCRs using tcrdist3 (v0.2.2)  
606 (91), with a tcrdist3 distance of less or equal to 12 per alpha and beta chain (translating  
607 to one amino acid mismatch per chain) used to assign possible targets for our TCRs.  
608 This was done for paired TCRab, and the specificity profiles were compared between MS  
609 patients and controls. For validation, TCRGP (1.0.0) (63) models were made for the 28  
610 HLA class I-restricted epitopes from endemic viruses (CMV, EBV, Influenza A). For the  
611 predictions, only CD8+ T cells were used and a threshold corresponding to a false positive  
612 rate (FPR) of 5% was determined for each epitope separately from the receiver operating  
613 characteristic (ROC) curves obtained from the cross-validation experiments, as described  
614 previously. For BCRs, clonality definition in scRepertoire was used, i.e., BCRs using the  
615 same V gene for both heavy and light chains (HC and LC), and that have >85% nucleotide  
616 similarity in the HC and LC CDR3s (with normalized Levenshtein distance) were grouped  
617 into one clonotype. For comparison with our results, we also used the clonotype definition  
618 by Lanz et al. 2022 (8), i.e., sharing the same HC and LC V and J genes, and exhibiting

619 >70% amino acid identity within the HC and LC CDR3s (with normalized Levenshtein  
620 distance).

621  
622 Human leukocyte antigen (HLA) genotypes were predicted from the scRNA-seq data with  
623 arcasHLA (92), which has recently been shown to have better accuracy than other similar  
624 tools (93). The HLA-DR15 allele with the strongest risk for MS, HLA-DRB1\*15:01(74),  
625 was present in all (3/3) of the healthy controls and half (3/6) of the MS patients (Data file  
626 S1), suggesting that the observed TCR/BCR repertoire changes in our MS patients are  
627 more likely caused by other reasons than due to HLA-DR15 allele.

### 628 **Intercellular communication analysis**

629 We used the NicheNet package (v. 2.0.1) (48) to study differences in intercellular  
630 communications between observed cell types. In each combination of sender and  
631 receiver cell type, genes that were expressed in at least 10% of the sender/receiver cell  
632 type population and present in the pre-built NicheNet prior ligand-receptor interaction  
633 model were chosen as potential receptor and ligand genes. In addition to ligand activity  
634 analysis, the ligands were prioritized based on condition-specificities of the ligands and  
635 receptors across all cell types to highlight any ligands and receptors expressed  
636 differentially between MS patients and controls. We visualized the top ligand-receptor  
637 pairs for each sender-receiver cell type combination using the mushroom plot function  
638 offered by NicheNet. In addition, the MultiNicheNet package (v. 1.0.3) (52) was used to  
639 observe differences between controls and MS patients. For the analysis, we followed the  
640 main steps in the MultiNicheNet vignette.

### 641 **Detection of viruses from scRNAseq data**

642 To detect any EBV-producing cells, we used the Vulture pipeline (62), which utilizes viral  
643 and prokaryote genome files from the ViruSITE (60) and NCBI (61) databases along with  
644 alignment tools to map 10x scRNA-seq reads to microbial genomes. Vulture was used  
645 together with the CellRanger alignment tool to map the raw scRNA-seq data to the  
646 microbial genomes. After performing QC on the mapped reads, we normalized the

647 obtained counts across each sample. This enabled comparing the counts of microbial  
648 features across samples.

### 649 **Hybrid-capture sequencing of DNA viruses from dcLN FNAs**

650 The DNA was extracted using the QIAamp DNA Mini Kit (Qiagen), following the  
651 manufacturer's protocol for tissue extraction. The extracts were eluted in 60 ul of AE  
652 buffer and the DNA was mechanically fragmented with a Covaris E220 with a target  
653 length of 200 nt. Subsequently, the libraries were prepared with the KAPA HyperPlus kit  
654 (Roche) using unique Dual Index Adapters (Roche). Targeted enrichment of the viral  
655 DNAs was performed using a custom panel of biotinylated RNA probes (Arbor  
656 Biosciences) as described by Toppinen et al (22). Each sample was individually  
657 enriched via two rounds of hybridization, following the manufacturer's recommendations  
658 for low-input DNA (MyBaits v5 kit; Arbor Biosciences). The probes were 100 bp in  
659 length and designed with 2X tiling. Kapa Universal Blockers (Roche) were used to block  
660 unspecific binding to the adapters during hybridization.

661  
662 During library preparation and viral enrichment, the libraries were amplified 3x13-25  
663 cycles. The clean-up steps were performed with 1x KAPA HyperPure Beads (Roche).  
664 The enriched libraries were quantified with the KAPA Library Quantification Kit (Roche)  
665 using Stratagene 3005P qPCR System (Agilent) and pooled for sequencing on  
666 NovaSeq 6000 (one lane, S4, PE151 kit; Illumina).

667

### 668 **Data analysis of hybrid-capture sequencing**

669 The data analysis was done with TRACESPipeLite, a streamlined version of  
670 TRACESPipe (94). The paired-end reads were trimmed and collapsed with  
671 AdapterRemoval, cutting ambiguous bases at the 5'/3' termini with quality scores below  
672 or equal to two. Reads shorter than 20 bases were discarded. FALCON-meta was used  
673 to find the highest similar reference from the NCBI viral database (95). The reads were  
674 aligned with BWA (96) using a seed length of 1000 and a maximum diff of 0.01. Read  
675 duplicates were removed with SAMtools (97) and the consensus sequences were



676 reconstructed with BCFtools (98). The coverage profiles were created with BEDtools  
677 (99). When in low breadth coverage (< 10%), the individual reads were manually  
678 inspected and confirmed by BLAST. The pipeline is freely available, under the MIT  
679 license, at <https://github.com/viromelab/TRACESPipeLite>, along with the code (included  
680 in the TRACESPipeLite repository).

## 681 **Quantitative multiplex PCR (qPCR) of saliva**

682 DNA extraction was optimized by adapting the protocol from Qiagen QIAamp DNA  
683 Blood Mini Kit and Qiagen DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) to get  
684 the highest yield of DNA. Initially, 8 ml of phosphate-buffered saline (PBS) (Lonza,  
685 Basel, Switzerland) was added to 2 ml of each saliva sample. The samples were then  
686 centrifuged at 1800 g for 10 minutes. The pellet was resuspended in 180 µl ATL buffer  
687 by pipetting up and down. The sample was pipetted into a new tube with 40 µl  
688 proteinase K, vortexed, and incubated at 56°C with shaking for 1 h. After this, 200 µl AL  
689 buffer was added followed by vortex and incubation at 70°C for 10s min. From here, the  
690 protocol continued following the Qiagen QIAamp DNA Blood Mini Kit Spin Protocol. In  
691 the last step, DNA was eluted into 60 µl AE buffer with an incubation time of 5 min. The  
692 samples were stored at -20°C until further processing.

693  
694 Multiplex qPCR method HERQ-9 was used to detect and quantify nine HHVs  
695 simultaneously from the saliva samples as described earlier by Pyöriä et al (100).  
696 Briefly, HERQ-9 is designed in three triplex-qPCR reactions, the first one amplifying  
697 herpes simplex viruses 1 and 2 (HSV-1 and 2) and varicella-zoster virus (VZV), the  
698 second one amplifying EBV, human cytomegalovirus (HCMV), and Kaposi's sarcoma-  
699 associated herpesvirus (KSHV), and the third one amplifying HHV-6A, -6B, and -7. The  
700 viral loads were normalized per 10<sup>6</sup> cells, determined with the human single-copy gene  
701 RNase P qPCR (101).

## 702 **Flow cytometry**

703 For cell surface staining, cells were suspended in an antibody cocktail containing  
704 LIVE/DEAD® Fixable Green Dead Cell Stain (ThermoFisher), which was prepared

705 using Brilliant Stain Buffer (BD Biosciences). The cell suspension was then incubated at  
706 +4°C for 30 minutes and subsequently washed twice with FACS staining buffer (PBS,  
707 pH 7.4, 10% FBS, and 2 mM EDTA). Flow cytometry data were acquired with LSR  
708 Fortessa (BD Biosciences) and analyzed with FlowJo (BD Biosciences, LLC). Detailed  
709 information about the antibodies used in this study can be found in Data file S13.

## 710 **Statistics**

711 Either the t-test or evaluation of the standardized Pearson residuals using the Chi-  
712 Square test was used to compare two different categories. In the chi-squared test, all  
713 cells were pooled by subject group and the overall cell type distribution frequency of the  
714 standardized Pearson residuals was compared between MS patients and healthy  
715 controls. Euclidean dissimilarity distances and either Ward's or complete agglomerative  
716 clustering were used in the correlation plots. In differentially expressing markers (both  
717 scRNA-seq and CITE-seq) analysis, the non-parametric Wilcoxon rank sum test was  
718 used and adjustments for multiple testing were performed with Bonferroni correction.  
719 Nominal and adjusted p-values ( $P_{adj}$ ) of less than 0.05 were considered significant. In  
720 the box plots, the vertical line corresponds to the median, the box corresponds to the  
721 interquartile range (IQR), and the whiskers are  $1.5 \times$  the IQR. All calculations were done  
722 with R (4.2.1, 4.3.1) or Python (3.7.4).

## 723 **Supplementary Materials**

724 Supplementary Material on cluster phenotyping

725 Supplementary Figures 1-5

726 Description of supplementary datafiles

727

## 728 References

- 729 1. C. Walton, R. King, L. Rechtman, W. Kaye, E. Leray, R. A. Marrie, N. Robertson, N.  
730 La Rocca, B. Uitdehaag, I. van der Mei, M. Wallin, A. Helme, C. Angood Napier, N.  
731 Rijke, P. Baneke, Rising prevalence of multiple sclerosis worldwide: Insights from  
732 the Atlas of MS, third edition. *Mult. Scler.* **26**, 1816–1821 (2020).
- 733 2. J. M. Fletcher, S. J. Lalor, C. M. Sweeney, N. Tubridy, K. H. G. Mills, T cells in  
734 multiple sclerosis and experimental autoimmune encephalomyelitis. *Clin. Exp.*  
735 *Immunol.* **162**, 1–11 (2010).
- 736 3. O. L. Hatton, A. Harris-Arnold, S. Schaffert, S. M. Krams, O. M. Martinez, The  
737 interplay between Epstein-Barr virus and B lymphocytes: implications for infection,  
738 immunity, and disease. *Immunol. Res.* **58**, 268–276 (2014).
- 739 4. S. Abrahamyan, B. Eberspächer, M.-M. Hoshi, L. Aly, F. Luessi, S. Groppa, L.  
740 Klotz, S. G. Meuth, C. Schroeder, T. Grüter, B. Tackenberg, F. Paul, F. Then-  
741 Bergh, T. Kümpfel, F. Weber, M. Stangel, A. Bayas, B. Wildemann, C. Heesen, U.  
742 Zettl, C. Warnke, G. Antony, N. Hessler, H. Wiendl, S. Bittner, B. Hemmer, R. Gold,  
743 A. Salmen, K. Ruprecht, German Competence Network Multiple Sclerosis  
744 (KKNMS), Other members of the KKNMS that acted as collaborators in this study,  
745 Complete Epstein-Barr virus seropositivity in a large cohort of patients with early  
746 multiple sclerosis. *J. Neurol. Neurosurg. Psychiatry.* **91**, 681–686 (2020).
- 747 5. R. Dobson, J. Kuhle, J. Middeldorp, G. Giovannoni, Epstein-Barr-negative MS: a  
748 true phenomenon? *Neurol Neuroimmunol Neuroinflamm.* **4**, e318 (2017).
- 749 6. K. Bjornevik, M. Cortese, B. C. Healy, J. Kuhle, M. J. Mina, Y. Leng, S. J. Elledge,  
750 D. W. Niebuhr, A. I. Scher, K. L. Munger, A. Ascherio, Longitudinal analysis reveals  
751 high prevalence of Epstein-Barr virus associated with multiple sclerosis. *Science*  
752 (2022), doi:10.1126/science.abj8222.
- 753 7. S. S. Soldan, P. M. Lieberman, Epstein-Barr virus and multiple sclerosis. *Nat. Rev.*  
754 *Microbiol.* **21**, 51–64 (2023).
- 755 8. T. V. Lanz, R. C. Brewer, P. P. Ho, J.-S. Moon, K. M. Jude, D. Fernandez, R. A.  
756 Fernandes, A. M. Gomez, G.-S. Nadj, C. M. Bartley, R. D. Schubert, I. A. Hawes,  
757 S. E. Vazquez, M. Iyer, J. B. Zuchero, B. Teegen, J. E. Dunn, C. B. Lock, L. B.  
758 Kipp, V. C. Cotham, B. M. Ueberheide, B. T. Aftab, M. S. Anderson, J. L. DeRisi, M.  
759 R. Wilson, R. J. M. Bashford-Rogers, M. Platten, K. C. Garcia, L. Steinman, W. H.  
760 Robinson, Clonally Expanded B Cells in Multiple Sclerosis Bind EBV EBNA1 and  
761 GlialCAM. *Nature* (2022), doi:10.1038/s41586-022-04432-7.
- 762 9. D. F. Angelini, B. Serafini, E. Piras, M. Severa, E. M. Coccia, B. Rosicarelli, S.  
763 Ruggieri, C. Gasperini, F. Buttari, D. Centonze, R. Mechelli, M. Salvetti, G.  
764 Borsellino, F. Aloisi, L. Battistini, Increased CD8+ T cell response to Epstein-Barr  
765 virus lytic antigens in the active phase of multiple sclerosis. *PLoS Pathog.* **9**,  
766 e1003220 (2013).

- 767 10. G. P. van Nierop, J. Mautner, J. G. Mitterreiter, R. Q. Hintzen, G. M. G. M. Verjans,  
768 Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr  
769 virus proteins. *Mult. Scler.* **22**, 279–291 (2016).
- 770 11. M. Abdel-Aziz, H. El-Hoshy, M. Rashed, M. Qotb, S. Awad, N. Naguib, Epstein-Barr  
771 virus infection as a cause of cervical lymphadenopathy in children. *Int. J. Pediatr.*  
772 *Otorhinolaryngol.* **75**, 564–567 (2011).
- 773 12. B. A. Plog, M. Nedergaard, The Glymphatic System in Central Nervous System  
774 Health and Disease: Past, Present, and Future. *Annu. Rev. Pathol.* **13**, 379–394  
775 (2018).
- 776 13. M. S. Albayram, G. Smith, F. Tufan, I. S. Tuna, M. Bostancıoğlu, M. Zile, O.  
777 Albayram, Non-invasive MR imaging of human brain lymphatic networks with  
778 connections to cervical lymph nodes. *Nat. Commun.* **13**, 203 (2022).
- 779 14. M. van Zwam, R. Huizinga, M.-J. Melief, A. F. Wierenga-Wolf, M. van Meurs, J. S.  
780 Voerman, K. P. H. Biber, H. W. G. M. Boddeke, U. E. Höpken, C. Meisel, A. Meisel,  
781 I. Bechmann, R. Q. Hintzen, B. A. 't Hart, S. Amor, J. D. Laman, L. A. Boven, Brain  
782 antigens in functionally distinct antigen-presenting cell populations in cervical lymph  
783 nodes in MS and EAE. *J. Mol. Med.* **87**, 273–286 (2009).
- 784 15. F. Di Giuliano, M. Albanese, E. Picchi, F. Mori, F. Buttari, G. A. Marfia, F. Garaci,  
785 N. B. Mercuri, R. Floris, D. Centonze, S. Marziali, Abnormal cervical lymph nodes in  
786 multiple sclerosis: a preliminary ultrasound study. *Radiol. Med.* **123**, 202–208  
787 (2018).
- 788 16. J. N. H. Stern, G. Yaari, J. A. Vander Heiden, G. Church, W. F. Donahue, R. Q.  
789 Hintzen, A. J. Huttner, J. D. Laman, R. M. Nagra, A. Nylander, D. Pitt, S. Ramanan,  
790 B. A. Siddiqui, F. Vigneault, S. H. Kleinstein, D. A. Hafler, K. C. O'Connor, B cells  
791 populating the multiple sclerosis brain mature in the draining cervical lymph nodes.  
792 *Sci. Transl. Med.* **6**, 248ra107-248ra107 (2014).
- 793 17. C. Gago da Graça, L. G. M. van Baarsen, R. E. Mebius, Tertiary Lymphoid  
794 Structures: Diversity in Their Development, Composition, and Role. *J. Immunol.*  
795 **206**, 273–281 (2021).
- 796 18. O. W. Howell, C. A. Reeves, R. Nicholas, D. Carassiti, B. Radotra, S. M.  
797 Gentleman, B. Serafini, F. Aloisi, F. Roncaroli, R. Magliozzi, R. Reynolds,  
798 Meningeal inflammation is widespread and linked to cortical pathology in multiple  
799 sclerosis. *Brain.* **134**, 2755–2771 (2011).
- 800 19. M. Stebegg, S. D. Kumar, A. Silva-Cayetano, V. R. Fonseca, M. A. Linterman, L.  
801 Graca, Regulation of the Germinal Center Response. *Front. Immunol.* **9**, 2469  
802 (2018).
- 803 20. M. Puthenparampil, A. Zito, G. Pantano, L. Federle, E. Stropparo, S. Miante, G. De  
804 Silvestro, M. Plebani, P. Gallo, Peripheral imbalanced TFH/TFR ratio correlates

- 805 with intrathecal IgG synthesis in multiple sclerosis at clinical onset. *Mult. Scler.*  
806 **2018/06/09**, 1352458518779951 (2018).
- 807 21. C. Havenar-Daughton, I. G. Newton, S. Y. Zare, S. M. Reiss, B. Schwan, M. J. Suh,  
808 F. Hasteh, G. Levi, S. Crotty, Normal human lymph node T follicular helper cells  
809 and germinal center B cells accessed via fine needle aspirations. *J. Immunol.*  
810 *Methods.* **479**, 112746 (2020).
- 811 22. M. Toppinen, D. Pratas, E. Väisänen, M. Söderlund-Venermo, K. Hedman, M. F.  
812 Perdomo, A. Sajantila, The landscape of persistent human DNA viruses in femoral  
813 bone. *Forensic Sci. Int. Genet.* **48**, 102353 (2020).
- 814 23. Y. Hao, S. Hao, E. Andersen-Nissen, W. M. Mauck 3rd, S. Zheng, A. Butler, M. J.  
815 Lee, A. J. Wilk, C. Darby, M. Zager, P. Hoffman, M. Stoeckius, E. Papalexi, E. P.  
816 Mimitou, J. Jain, A. Srivastava, T. Stuart, L. M. Fleming, B. Yeung, A. J. Rogers, J.  
817 M. McElrath, C. A. Blish, R. Gottardo, P. Smibert, R. Satija, Integrated analysis of  
818 multimodal single-cell data. *Cell.* **184**, 3573-3587.e29 (2021).
- 819 24. M. Büttner, Z. Miao, F. A. Wolf, S. A. Teichmann, F. J. Theis, A test metric for  
820 assessing single-cell RNA-seq batch correction. *Nat. Methods.* **16**, 43–49 (2019).
- 821 25. D. Aran, A. P. Looney, L. Liu, E. Wu, V. Fong, A. Hsu, S. Chak, R. P. Naikawadi, P.  
822 J. Wolters, A. R. Abate, A. J. Butte, M. Bhattacharya, Reference-based analysis of  
823 lung single-cell sequencing reveals a transitional profibrotic macrophage. *Nat.*  
824 *Immunol.* **20**, 163–172 (2019).
- 825 26. G. Monaco, B. Lee, W. Xu, S. Mustafah, Y. Y. Hwang, C. Carré, N. Burdin, L.  
826 Visan, M. Ceccarelli, M. Poidinger, A. Zippelius, J. Pedro de Magalhães, A. Larbi,  
827 RNA-Seq Signatures Normalized by mRNA Abundance Allow Absolute  
828 Deconvolution of Human Immune Cell Types. *Cell Rep.* **26**, 1627-1640.e7 (2019).
- 829 27. P. Schaerli, K. Willimann, A. B. Lang, M. Lipp, P. Loetscher, B. Moser, CXC  
830 chemokine receptor 5 expression defines follicular homing T cells with B cell helper  
831 function. *J. Exp. Med.* **192**, 1553–1562 (2000).
- 832 28. D. Yu, S. Rao, L. M. Tsai, S. K. Lee, Y. He, E. L. Sutcliffe, M. Srivastava, M.  
833 Linterman, L. Zheng, N. Simpson, J. I. Ellyard, I. A. Parish, C. S. Ma, Q.-J. Li, C. R.  
834 Parish, C. R. Mackay, C. G. Vinuesa, The transcriptional repressor Bcl-6 directs T  
835 follicular helper cell lineage commitment. *Immunity.* **31**, 457–468 (2009).
- 836 29. Y. S. Choi, R. Kageyama, D. Eto, T. C. Escobar, R. J. Johnston, L. Monticelli, C.  
837 Lao, S. Crotty, ICOS receptor instructs T follicular helper cell versus effector cell  
838 differentiation via induction of the transcriptional repressor Bcl6. *Immunity.* **34**, 932–  
839 946 (2011).
- 840 30. W. Xu, X. Zhao, X. Wang, H. Feng, M. Gou, W. Jin, X. Wang, X. Liu, C. Dong, The  
841 Transcription Factor Tox2 Drives T Follicular Helper Cell Development via  
842 Regulating Chromatin Accessibility. *Immunity.* **51**, 826-839.e5 (2019).

- 843 31. J. Shi, S. Hou, Q. Fang, X. Liu, X. Liu, H. Qi, PD-1 Controls Follicular T Helper Cell  
844 Positioning and Function. *Immunity*. **49**, 264-274 e4 (2018).
- 845 32. J. Hu, C. Havenar-Daughton, S. Crotty, Modulation of SAP dependent T:B cell  
846 interactions as a strategy to improve vaccination. *Curr. Opin. Virol.* **3**, 363–370  
847 (2013).
- 848 33. A. R. Dvorscek, C. I. McKenzie, M. J. Robinson, Z. Ding, C. Pitt, K. O'Donnell, D.  
849 Zotos, R. Brink, D. M. Tarlinton, I. Quast, IL-21 has a critical role in establishing  
850 germinal centers by amplifying early B cell proliferation. *EMBO Rep.* **23**, e54677  
851 (2022).
- 852 34. C.-H. Yeh, J. Finney, T. Okada, T. Kurosaki, G. Kelsoe, Primary germinal center-  
853 resident T follicular helper cells are a physiologically distinct subset of CXCR5hiPD-  
854 1hi T follicular helper cells. *Immunity*. **55**, 272-289.e7 (2022).
- 855 35. S. T. Kim, J.-Y. Choi, B. Lainez, V. P. Schulz, D. E. Karas, E. D. Baum, J. Setlur, P.  
856 G. Gallagher, J. Craft, Human Extrafollicular CD4+ Th Cells Help Memory B Cells  
857 Produce Igs. *J. Immunol.* **201**, 1359–1372 (2018).
- 858 36. V. Panneton, B. C. Mindt, Y. Bouklouch, A. Bouchard, S. Mohammaei, J. Chang, N.  
859 Diamantopoulos, M. Witalis, J. Li, A. Stancescu, J. E. Bradley, T. D. Randall, J. H.  
860 Fritz, W.-K. Suh, ICOS costimulation is indispensable for the differentiation of T  
861 follicular regulatory cells. *Life Sci Alliance*. **6** (2023), doi:10.26508/lsa.202201615.
- 862 37. L. Mesin, J. Ersching, G. D. Victora, Germinal Center B Cell Dynamics. *Immunity*.  
863 **45**, 471–482 (2016).
- 864 38. C. Lamagna, Y. Hu, A. L. DeFranco, C. A. Lowell, B cell-specific loss of Lyn kinase  
865 leads to autoimmunity. *J. Immunol.* **192**, 919–928 (2014).
- 866 39. Y. Wang, R. H. Carter, CD19 regulates B cell maturation, proliferation, and positive  
867 selection in the FDC zone of murine splenic germinal centers. *Immunity*. **22**, 749–  
868 761 (2005).
- 869 40. A. Erdei, K. G. Kovács, Z. Nagy-Baló, S. Lukácsi, B. Mácsik-Valent, I. Kurucz, Z.  
870 Bajtay, New aspects in the regulation of human B cell functions by complement  
871 receptors CR1, CR2, CR3 and CR4. *Immunol. Lett.* **237**, 42–57 (2021).
- 872 41. M. Meister, M. Papatriantafyllou, V. Nordström, V. Kumar, J. Ludwig, K. O. Lui, A.  
873 S. Boyd, Z. V. Popovic, T. H. Fleming, G. Moldenhauer, P. P. Nawroth, H.-J.  
874 Gröne, H. Waldmann, T. Oelert, B. Arnold, Dickkopf-3, a tissue-derived modulator  
875 of local T-cell responses. *Front. Immunol.* **6**, 78 (2015).
- 876 42. R. J. Johnston, L. Comps-Agrar, J. Hackney, X. Yu, M. Huseni, Y. Yang, S. Park,  
877 V. Javinal, H. Chiu, B. Irving, D. L. Eaton, J. L. Grogan, The immunoreceptor TIGIT  
878 regulates antitumor and antiviral CD8(+) T cell effector function. *Cancer Cell*. **26**,  
879 923–937 (2014).

- 880 43. R. A. Elsner, M. J. Shlomchik, Germinal Center and Extrafollicular B Cell  
881 Responses in Vaccination, Immunity, and Autoimmunity. *Immunity*. **53**, 1136–1150  
882 (2020).
- 883 44. S. A. Jenks, K. S. Cashman, E. Zumaquero, U. M. Marigorta, A. V. Patel, X. Wang,  
884 D. Tomar, M. C. Woodruff, Z. Simon, R. Bugrovsky, E. L. Blalock, C. D. Scharer, C.  
885 M. Tipton, C. Wei, S. S. Lim, M. Petri, T. B. Niewold, J. H. Anolik, G. Gibson, F. E.-  
886 H. Lee, J. M. Boss, F. E. Lund, I. Sanz, Distinct Effector B Cells Induced by  
887 Unregulated Toll-like Receptor 7 Contribute to Pathogenic Responses in Systemic  
888 Lupus Erythematosus. *Immunity*. **49**, 725-739.e6 (2018).
- 889 45. I. Sanz, C. Wei, S. A. Jenks, K. S. Cashman, C. Tipton, M. C. Woodruff, J. Hom, F.  
890 E.-H. Lee, Challenges and Opportunities for Consistent Classification of Human B  
891 Cell and Plasma Cell Populations. *Front. Immunol.* **10**, 2458 (2019).
- 892 46. D. Morgan, V. Tergaonkar, Unraveling B cell trajectories at single cell resolution.  
893 *Trends Immunol.* **43**, 210–229 (2022).
- 894 47. P. Milpied, I. Cervera-Marzal, M.-L. Mollichella, B. Tesson, G. Brisou, A. Traverse-  
895 Glehen, G. Salles, L. Spinelli, B. Nadel, Human germinal center transcriptional  
896 programs are de-synchronized in B cell lymphoma. *Nat. Immunol.* **19**, 1013–1024  
897 (2018).
- 898 48. R. Browaeys, W. Saelens, Y. Saeys, NicheNet: modeling intercellular  
899 communication by linking ligands to target genes. *Nat. Methods.* **17**, 159–162  
900 (2020).
- 901 49. G. D. Victora, M. C. Nussenzweig, Germinal Centers. *Annu. Rev. Immunol.* **40**,  
902 413–442 (2022).
- 903 50. A. Biram, N. Davidzohn, Z. Shulman, T cell interactions with B cells during germinal  
904 center formation, a three-step model. *Immunol. Rev.* **288**, 37–48 (2019).
- 905 51. K. L. Good-Jacobson, E. Song, S. Anderson, A. H. Sharpe, M. J. Shlomchik, CD80  
906 expression on B cells regulates murine T follicular helper development, germinal  
907 center B cell survival, and plasma cell generation. *J. Immunol.* **188**, 4217–4225  
908 (2012).
- 909 52. R. Browaeys, J. Gilis, C. Sang-Aram, P. De Bleser, L. Hoste, S. Tavernier, D.  
910 Lambrechts, R. Seurinck, Y. Saeys, MultiNicheNet: a flexible framework for  
911 differential cell-cell communication analysis from multi-sample multi-condition  
912 single-cell transcriptomics data. *bioRxiv* (2023), p. 2023.06.13.544751, ,  
913 doi:10.1101/2023.06.13.544751.
- 914 53. N. Giovannone, L. K. Smith, B. Treanor, C. J. Dimitroff, Galectin-Glycan  
915 Interactions as Regulators of B Cell Immunity. *Front. Immunol.* **9**, 2839 (2018).

- 916 54. M. A. Linterman, W. Pierson, S. K. Lee, A. Kallies, S. Kawamoto, T. F. Rayner, M.  
917 Srivastava, D. P. Divekar, L. Beaton, J. J. Hogan, S. Fagarasan, A. Liston, K. G. C.  
918 Smith, C. G. Vinuesa, Foxp3<sup>+</sup> follicular regulatory T cells control the germinal  
919 center response. *Nat. Med.* **17**, 975–982 (2011).
- 920 55. V. R. Fonseca, F. Ribeiro, L. Graca, T follicular regulatory (Tfr) cells: Dissecting the  
921 complexity of Tfr-cell compartments. *Immunol. Rev.* **288**, 112–127 (2019).
- 922 56. A. Naji, C. Menier, F. Morandi, S. Agaagué, G. Maki, E. Ferretti, S. Bruel, V.  
923 Pistoia, E. D. Carosella, N. Rouas-Freiss, Binding of HLA-G to ITIM-bearing Ig-like  
924 transcript 2 receptor suppresses B cell responses. *J. Immunol.* **192**, 1536–1546  
925 (2014).
- 926 57. W. Saelens, R. Cannoodt, H. Todorov, Y. Saeys, A comparison of single-cell  
927 trajectory inference methods. *Nat. Biotechnol.* **37**, 547–554 (2019).
- 928 58. C. Le Coz, D. A. Oldridge, R. S. Herati, N. De Luna, J. Garifallou, E. Cruz Cabrera,  
929 J. P. Belman, D. Poeschl, L. V. Silva, A. V. C. Knox, W. Reid, S. Yoon, K. B. Zur, S.  
930 D. Handler, H. Hakonarson, E. J. Wherry, M. Gonzalez, N. Romberg, Human T  
931 follicular helper clones seed the germinal center-resident regulatory pool. *Sci*  
932 *Immunol.* **8**, eade8162 (2023).
- 933 59. L. Pyöriä, D. Pratas, M. Toppinen, K. Hedman, A. Sajantila, M. F. Perdomo,  
934 Unmasking the tissue-resident eukaryotic DNA virome in humans. *Nucleic Acids*  
935 *Res.* **51**, 3223–3239 (2023).
- 936 60. M. Stano, G. Beke, L. Klucar, viruSITE—integrated database for viral genomics.  
937 *Database* . **2016**, baw162 (2016).
- 938 61. E. W. Sayers, E. E. Bolton, J. R. Brister, K. Canese, J. Chan, D. C. Comeau, R.  
939 Connor, K. Funk, C. Kelly, S. Kim, T. Madej, A. Marchler-Bauer, C. Lanczycki, S.  
940 Lathrop, Z. Lu, F. Thibaud-Nissen, T. Murphy, L. Phan, Y. Skripchenko, T. Tse, J.  
941 Wang, R. Williams, B. W. Trawick, K. D. Pruitt, S. T. Sherry, Database resources of  
942 the national center for biotechnology information. *Nucleic Acids Res.* **50**, D20–D26  
943 (2022).
- 944 62. J. Chen, D. Yin, H. Y. H. Wong, X. Duan, K. H. O. Yu, J. W. K. Ho, Vulture: Cloud-  
945 enabled scalable mining of microbial reads in public scRNA-seq data. *bioRxiv*  
946 (2023), p. 2023.02.13.528411, , doi:10.1101/2023.02.13.528411.
- 947 63. E. Jokinen, J. Huuhtanen, S. Mustjoki, M. Heinonen, H. Lähdesmäki, Predicting  
948 recognition between T cell receptors and epitopes with TCRGP. *PLoS Comput.*  
949 *Biol.* **17**, e1008814 (2021).
- 950 64. D. Schafflick, C. A. Xu, M. Hartlehnert, M. Cole, A. Schulte-Mecklenbeck, T.  
951 Lautwein, J. Wolbert, M. Heming, S. G. Meuth, T. Kuhlmann, C. C. Gross, H.  
952 Wiendl, N. Yosef, G. Meyer Zu Horste, Integrated single cell analysis of blood and  
953 cerebrospinal fluid leukocytes in multiple sclerosis. *Nat. Commun.* **11**, 247 (2020).



- 954 65. F. Ingelfinger, L. A. Gerdes, V. Kavaka, S. Krishnarajah, E. Friebel, E. Galli, P.  
955 Zwicky, R. Furrer, C. Peukert, C.-A. Dutertre, K. M. Eglseer, F. Ginhoux, A. Flierl-  
956 Hecht, T. Kümpfel, D. De Feo, B. Schreiner, S. Mundt, M. Kerschensteiner, R.  
957 Hohlfeld, E. Beltrán, B. Becher, Twin study reveals non-heritable immune  
958 perturbations in multiple sclerosis. *Nature*. **603**, 152–158 (2022).
- 959 66. A. Ramesh, R. D. Schubert, A. L. Greenfield, R. Dandekar, R. Loudermilk, J. J.  
960 Sabatino Jr, M. T. Koelzer, E. B. Tran, K. Koshal, K. Kim, A.-K. Pröbstel, D. Banerji,  
961 University of California, San Francisco MS-EPIC Team, C.-Y. Guo, A. J. Green, R.  
962 M. Bove, J. L. DeRisi, J. M. Gelfand, B. A. C. Cree, S. S. Zamvil, S. E. Baranzini, S.  
963 L. Hauser, M. R. Wilson, A pathogenic and clonally expanded B cell transcriptome  
964 in active multiple sclerosis. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 22932–22943  
965 (2020).
- 966 67. J. Leffler, S. Trend, N. C. Ward, G. E. Grau, S. Hawke, S. N. Byrne, A. G.  
967 Kermode, M. A. French, P. H. Hart, Circulating Memory B Cells in Early Multiple  
968 Sclerosis Exhibit Increased IgA+ Cells, Globally Decreased BAFF-R Expression  
969 and an EBV-Related IgM+ Cell Signature. *Front. Immunol.* **13**, 812317 (2022).
- 970 68. R. Shinnakasu, T. Inoue, K. Kometani, S. Moriyama, Y. Adachi, M. Nakayama, Y.  
971 Takahashi, H. Fukuyama, T. Okada, T. Kurosaki, Regulated selection of germinal-  
972 center cells into the memory B cell compartment. *Nat. Immunol.* **17**, 861–869  
973 (2016).
- 974 69. T. Arulraj, S. C. Binder, M. Meyer-Hermann, Investigating the Mechanism of  
975 Germinal Center Shutdown. *Front. Immunol.* **13**, 922318 (2022).
- 976 70. L. A. Vella, R. S. Herati, E. J. Wherry, CD4(+) T Cell Differentiation in Chronic Viral  
977 Infections: The Tfh Perspective. *Trends Mol. Med.* **23**, 1072–1087 (2017).
- 978 71. B. Serafini, B. Rosicarelli, D. Franciotta, R. Magliozzi, R. Reynolds, P. Cinque, L.  
979 Andreoni, P. Trivedi, M. Salvetti, A. Faggioni, F. Aloisi, Dysregulated Epstein-Barr  
980 virus infection in the multiple sclerosis brain. *J. Exp. Med.* **204**, 2899–2912 (2007).
- 981 72. S. N. Willis, C. Stadelmann, S. J. Rodig, T. Caron, S. Gattenloehner, S. S. Mallozzi,  
982 J. E. Roughan, S. E. Almendinger, M. M. Blewett, W. Brück, D. A. Hafler, K. C.  
983 O'Connor, Epstein-Barr virus infection is not a characteristic feature of multiple  
984 sclerosis brain. *Brain*. **132**, 3318–3328 (2009).
- 985 73. L. A. N. Peferoen, F. Lamers, L. N. R. Lodder, W. H. Gerritsen, I. Huitinga, J.  
986 Melief, G. Giovannoni, U. Meier, R. Q. Hintzen, G. M. G. M. Verjans, G. P. van  
987 Nierop, W. Vos, R. M. B. Peferoen-Baert, J. M. Middeldorp, P. van der Valk, S.  
988 Amor, Epstein Barr virus is not a characteristic feature in the central nervous  
989 system in established multiple sclerosis. *Brain*. **133** (2010), p. e137.
- 990 74. I. Jelcic, F. Al Nimer, J. Wang, V. Lentsch, R. Planas, I. Jelcic, A. Madjovski, S.  
991 Ruhrmann, W. Faigle, K. Frauenknecht, C. Pinilla, R. Santos, C. Hammer, Y. Ortiz,  
992 L. Opitz, H. Grönlund, G. Rogler, O. Boyman, R. Reynolds, A. Lutterotti, M.

- 993 Khademi, T. Olsson, F. Piehl, M. Sospedra, R. Martin, Memory B Cells Activate  
994 Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis. *Cell*. **175**, 85-  
995 100.e23 (2018).
- 996 75. J. Wang, I. Jelcic, L. Mühlenbruch, V. Haunerding, N. C. Toussaint, Y. Zhao, C.  
997 Cruciani, W. Faigle, R. Naghavian, M. Foege, T. M. C. Binder, T. Eiermann, L.  
998 Opitz, L. Fuentes-Font, R. Reynolds, W. W. Kwok, J. T. Nguyen, J.-H. Lee, A.  
999 Lutterotti, C. Münz, H.-G. Rammensee, M. Hauri-Hohl, M. Sospedra, S. Stevanovic,  
1000 R. Martin, HLA-DR15 Molecules Jointly Shape an Autoreactive T Cell Repertoire in  
1001 Multiple Sclerosis. *Cell*. **183**, 1264-1281.e20 (2020).
- 1002 76. R. M. Gieß, C. Pfuhl, J. R. Behrens, L. Rasche, E. Freitag, N. Khalighy, C. Otto, J.  
1003 Wuerfel, A. U. Brandt, J. Hofmann, B. Eberspächer, J. Bellmann-Strobl, F. Paul, K.  
1004 Ruprecht, Epstein-Barr virus antibodies in serum and DNA load in saliva are not  
1005 associated with radiological or clinical disease activity in patients with early multiple  
1006 sclerosis. *PLoS One*. **12**, e0175279 (2017).
- 1007 77. C. Yea, R. Tellier, P. Chong, G. Westmacott, R. A. Marrie, A. Bar-Or, B. Banwell,  
1008 Canadian Pediatric Demyelinating Disease Network, Epstein-Barr virus in oral  
1009 shedding of children with multiple sclerosis. *Neurology*. **81**, 1392–1399 (2013).
- 1010 78. T. M. Yamawaki, D. R. Lu, D. C. Ellwanger, D. Bhatt, P. Manzanillo, V. Arias, H.  
1011 Zhou, O. K. Yoon, O. Homann, S. Wang, C.-M. Li, Systematic comparison of high-  
1012 throughput single-cell RNA-seq methods for immune cell profiling. *BMC Genomics*.  
1013 **22**, 66 (2021).
- 1014 79. Ø. Torkildsen, H. Nyland, H. Myrmed, K.-M. Myhr, Epstein-Barr virus reactivation  
1015 and multiple sclerosis. *Eur. J. Neurol*. **15**, 106–108 (2008).
- 1016 80. T. Schneider-Hohendorf, L. A. Gerdes, B. Pignolet, R. Gittelmann, P. Ostkamp, F.  
1017 Rubelt, C. Raposo, B. Tackenberg, M. Riepenhausen, C. Janoschka, C. Wünsch,  
1018 F. Bucciarelli, A. Flierl-Hecht, E. Beltrán, T. Kümpfel, K. Anslinger, C. C. Gross, H.  
1019 Chapman, I. Kaplan, D. Brassat, H. Wekerle, M. Kerschensteiner, L. Klotz, J. D.  
1020 Lünemann, R. Hohlfeld, R. Liblau, H. Wiendl, N. Schwab, Broader Epstein-Barr  
1021 virus-specific T cell receptor repertoire in patients with multiple sclerosis. *J. Exp.*  
1022 *Med*. **219** (2022), doi:10.1084/jem.20220650.
- 1023 81. E. D. SoRelle, N. M. Reinoso-Vizcaino, G. Q. Horn, M. A. Luftig, Epstein-Barr virus  
1024 perpetuates B cell germinal center dynamics and generation of autoimmune-  
1025 associated phenotypes in vitro. *Front. Immunol*. **13**, 1001145 (2022).
- 1026 82. A. J. Thompson, B. L. Banwell, F. Barkhof, W. M. Carroll, T. Coetzee, G. Comi, J.  
1027 Correale, F. Fazekas, M. Filippi, M. S. Freedman, K. Fujihara, S. L. Galetta, H. P.  
1028 Hartung, L. Kappos, F. D. Lublin, R. A. Marrie, A. E. Miller, D. H. Miller, X.  
1029 Montalban, E. M. Mowry, P. S. Sorensen, M. Tintoré, A. L. Traboulsee, M. Trojano,  
1030 B. M. J. Uitdehaag, S. Vukusic, E. Waubant, B. G. Weinshenker, S. C. Reingold, J.  
1031 A. Cohen, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.  
1032 *Lancet Neurol*. **17**, 162–173 (2018).

- 1033 83. C. H. Polman, S. C. Reingold, B. Banwell, M. Clanet, J. A. Cohen, M. Filippi, K.  
1034 Fujihara, E. Havrdova, M. Hutchinson, L. Kappos, F. D. Lublin, X. Montalban, P.  
1035 O'Connor, M. Sandberg-Wollheim, A. J. Thompson, E. Waubant, B. Weinschenker,  
1036 J. S. Wolinsky, Diagnostic criteria for multiple sclerosis: 2010 revisions to the  
1037 McDonald criteria. *Ann. Neurol.* **69**, 292–302 (2011).
- 1038 84. J. S. Turner, J. Q. Zhou, J. Han, A. J. Schmitz, A. A. Rizk, W. B. Alsoussi, T. Lei, M.  
1039 Amor, K. M. McIntire, P. Meade, S. Strohmeier, R. I. Brent, S. T. Richey, A. Haile,  
1040 Y. R. Yang, M. K. Klebert, T. Suessen, S. Teefey, R. M. Presti, F. Krammer, S. H.  
1041 Kleinstein, A. B. Ward, A. H. Ellebedy, Human germinal centres engage memory  
1042 and naive B cells after influenza vaccination. *Nature.* **586**, 127–132 (2020).
- 1043 85. J. W. Squair, M. Gautier, C. Kathe, M. A. Anderson, N. D. James, T. H. Hutson, R.  
1044 Hudelle, T. Qaiser, K. J. E. Matson, Q. Barraud, A. J. Levine, G. La Manno, M. A.  
1045 Skinnider, G. Courtine, Confronting false discoveries in single-cell differential  
1046 expression. *Nat. Commun.* **12**, 5692 (2021).
- 1047 86. M. I. Love, W. Huber, S. Anders, Moderated estimation of fold change and  
1048 dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 550 (2014).
- 1049 87. S. Draghici, P. Khatri, A. L. Tarca, K. Amin, A. Done, C. Voichita, C. Georgescu, R.  
1050 Romero, A systems biology approach for pathway level analysis. *Genome Res.* **17**,  
1051 1537–1545 (2007).
- 1052 88. C. Voichita, M. Donato, S. Draghici, "Incorporating Gene Significance in the Impact  
1053 Analysis of Signaling Pathways" in *2012 11th International Conference on Machine  
1054 Learning and Applications* (2012), vol. 1, pp. 126–131.
- 1055 89. N. Borchering, N. L. Bormann, G. Kraus, scRepertoire: An R-based toolkit for  
1056 single-cell immune receptor analysis. *F1000Res.* **9**, 47 (2020).
- 1057 90. M. Shugay, D. V. Bagaev, I. V. Zvyagin, R. M. Vroomans, J. C. Crawford, G.  
1058 Dolton, E. A. Komech, A. L. Sycheva, A. E. Koneva, E. S. Egorov, A. V. Eliseev, E.  
1059 Van Dyk, P. Dash, M. Attaf, C. Rius, K. Ladell, J. E. McLaren, K. K. Matthews, E. B.  
1060 Clemens, D. C. Douek, F. Luciani, D. van Baarle, K. Kedzierska, C. Kesmir, P. G.  
1061 Thomas, D. A. Price, A. K. Sewell, D. M. Chudakov, VDJdb: a curated database of  
1062 T-cell receptor sequences with known antigen specificity. *Nucleic Acids Res.* **46**,  
1063 D419–D427 (2018).
- 1064 91. K. Mayer-Blackwell, S. Schattgen, L. Cohen-Lavi, J. C. Crawford, A. Souquette, J.  
1065 A. Gaevert, T. Hertz, P. G. Thomas, P. Bradley, A. Fiore-Gartland, TCR meta-  
1066 clonotypes for biomarker discovery with tcrdist3 enabled identification of public,  
1067 HLA-restricted clusters of SARS-CoV-2 TCRs. *Elife.* **10**, e68605 (2021).
- 1068 92. R. Orenbuch, I. Filip, D. Comito, J. Shaman, I. Pe'er, R. Rabadan, arcashLA: high-  
1069 resolution HLA typing from RNAseq. *Bioinformatics.* **36**, 33–40 (2020).

- 1070 93. B. D. Solomon, H. Zheng, L. W. Dillon, J. D. Goldman, C. S. Hourigan, J. R. Heath,  
1071 P. Khatri, Prediction of HLA genotypes from single-cell transcriptome data. *Front.*  
1072 *Immunol.* **14**, 1146826 (2023).
- 1073 94. D. Pratas, M. Toppinen, L. Pyöriä, K. Hedman, A. Sajantila, M. F. Perdomo, A  
1074 hybrid pipeline for reconstruction and analysis of viral genomes at multi-organ level.  
1075 *Gigascience.* **9** (2020), doi:10.1093/gigascience/giaa086.
- 1076 95. D. Pratas, M. Hosseini, G. Grilo, A. J. Pinho, R. M. Silva, T. Caetano, J. Carneiro,  
1077 F. Pereira, Metagenomic Composition Analysis of an Ancient Sequenced Polar  
1078 Bear Jawbone from Svalbard. *Genes* . **9** (2018), doi:10.3390/genes9090445.
- 1079 96. H. Li, R. Durbin, Fast and accurate long-read alignment with Burrows-Wheeler  
1080 transform. *Bioinformatics.* **26**, 589–595 (2010).
- 1081 97. H. Li, B. Handsaker, A. Wysoker, T. Fennell, J. Ruan, N. Homer, G. Marth, G.  
1082 Abecasis, R. Durbin, 1000 Genome Project Data Processing Subgroup, The  
1083 Sequence Alignment/Map format and SAMtools. *Bioinformatics.* **25**, 2078–2079  
1084 (2009).
- 1085 98. H. Li, A statistical framework for SNP calling, mutation discovery, association  
1086 mapping and population genetical parameter estimation from sequencing data.  
1087 *Bioinformatics.* **27**, 2987–2993 (2011).
- 1088 99. A. R. Quinlan, *Curr. Protoc. Bioinformatics*, in press.
- 1089 100. L. Pyöriä, M. Jokinen, M. Toppinen, H. Salminen, T. Vuorinen, V.  
1090 Hukkanen, C. Schmotz, E. Elbasani, P. M. Ojala, K. Hedman, H. Välimaa, M. F.  
1091 Perdomo, HERQ-9 Is a New Multiplex PCR for Differentiation and Quantification of  
1092 All Nine Human Herpesviruses. *mSphere.* **5** (2020), doi:10.1128/mSphere.00265-  
1093 20.
- 1094 101. L. Pyöriä, M. Toppinen, E. Mäntylä, L. Hedman, L.-M. Aaltonen, M. Vihinen-  
1095 Ranta, T. Ilmarinen, M. Söderlund-Venermo, K. Hedman, M. F. Perdomo, Extinct  
1096 type of human parvovirus B19 persists in tonsillar B cells. *Nat. Commun.* **8**, 14930  
1097 (2017).
- 1098

1099 **Acknowledgments:**

1100 We are grateful for the patients and healthy controls for their participation, and without  
1101 whom this study would not have been possible. We thank Marjo Rissanen and Kalla-  
1102 Maria Tiilikainen for their help with sample processing. The authors would like to thank  
1103 the FIMM Single-Cell Analytics unit supported by HiLIFE and Biocenter Finland for  
1104 scRNA and CITE-seq services.

1105

1106 **Funding:**

1107 Academy of Finland grant 332186 (SML)  
1108 Competitive Research Funding of the State of Finland governed through Helsinki  
1109 University Hospital grant TYH2020317 (SML)  
1110 Finska Läkaresällskapet (SML)  
1111 Suomen MS-Säätiö (JS)  
1112 Emil Aaltonen Foundation (JS)  
1113 Instrumentarium Science Foundation (JS)  
1114 Suomen Lääketieteen säätiö grant 6006 (MP)  
1115 Liv och Hälsa (MP)

1116

1117 **Author contributions:**

1118 Conceptualization: SML, JS, MP, EK, PJT  
1119 Methodology: JS, DY, SML  
1120 Software: DY, JH  
1121 Validation: JS, DY, MP  
1122 Formal Analysis: JS, DY, NK, PD, JH, MP  
1123 Investigation: JS, PD, KN, GK, RL, MP, SML  
1124 Resources: SML, MS, EK, MP  
1125 Data Curation: JS, DY, NK, PD, KN, MP  
1126 Writing – Original Draft: JS, DY, NK, SML  
1127 Writing – Review & Editing: SML, JS, DY, JH, KN, PJT, EK, MP  
1128 Visualization: JS, DY, NK, JH  
1129 Supervision: EK, SML

1130 Project administration: JS, SML

1131 Funding acquisition: SML, EK, MP

1132

1133 **Competing interests:**

1134 SML: lecture fees Argenx, Biogen, Janssen, Merck, Novartis, Roche; congress  
1135 expenses Merck, Novartis; advisory fee Argenx, Novartis, Roche, Sanofi, UCB Pharma;  
1136 investigator for the clinical study Clarion (Merck) and sub-investigator for the clinical  
1137 study Fenhance (Roche)

1138 PJT: Congress expenses Biogen, Novartis, Merck KGaA, Teva; fees for lectures  
1139 Biogen, Roche, Novartis, Sanofi-Genzyme, Merck, Teva, Orion, Santen, Alexion.

1140

1141 **Data and materials availability:**


1142 The Seurat-objects of the processed scRNA-sequencing data including TCR and BCR  
1143 and CITE-seq data are available at Zenodo (10.5281/zenodo.10006020) with restricted  
1144 access due to GDPR regulations and data can be accessed by placing a request via  
1145 Zenodo. Differentially expressed gene sets are available in supplementary data files.

1146 The reconstructed near-complete HHV-7 genomes are available at GenBank  
1147 (OR634979 and OR634980). The code to reproduce the key findings is available on  
1148 GitHub ([https://github.com/SarkkinenJ/cervical\\_lymphnodes\\_MS.git](https://github.com/SarkkinenJ/cervical_lymphnodes_MS.git)).


1149

1150 **Figures:**


**A.**




**B.**




**C.**




**D.**




**E.**




**F.**



**G.**



**H.**




1152 **Fig. 1. Skewed B and T cell populations in MS dcLNs highlighting enlarged**  
1153 **memory B cell compartment**

1154 **(A)** Schematic diagram of study design, where the left panel illustrates sample collection  
1155 including ultrasound-guided fine-needle aspirations (FNA) of deep cervical lymph nodes  
1156 (dcLN). The right panel summarizes experiments performed for each subject. **(B)**  
1157 Uniform Manifold Approximation and Projection (UMAP) of identified dcLN scRNA-seq  
1158 cell clusters do not show a significant batch effect. **(C)** UMAP of identified cell clusters  
1159 based on a combination of automatic annotation with SingleR (the Monaco reference)  
1160 and manual annotation (in-house expertise) aided by the CITE-seq data. **(D-E)** Dotplot  
1161 of key scRNA-seq (D) and CITE-seq (E) marker expression profiles in identified T and B  
1162 cell subsets. **(F)** Bar plot of dcLN cell type proportions. **(G)** Box plot of cell type  
1163 proportions in MS patients compared to controls using an unpaired t-test ( $p$ -values  $< 0.1$   
1164 are shown). The MS patient with an active relapse is highlighted with a triangle. **(H)** Bar  
1165 plot of standardized Pearson residuals of cell subset numbers using Chi-squared test.  
1166 Increased (red) and decreased (blue) cell subsets in MS patients' dcLNs are highlighted  
1167 compared to healthy controls. Dashed red lines at  $\pm 3.65$  correspond to Bonferroni  
1168 corrected  $p$ -values ( $< 0.00013$ ) in the null distribution of standardized residuals.  
1169 Abbreviations: GC, Germinal center; NK, Natural killer; PB, plasmablast; Tfh, T follicular  
1170 helper, Tfr, T follicular regulator; T reg, regulatory T cell.

1171







1172

1173 **Fig. 2. Further analysis of the B cell compartment in MS dcLNs shows increased**  
 1174 **double negative B cells**

1175 (A) UMAP of further clustered naïve and memory B cells. (B) Violin plot presenting the  
 1176 expression of key transcripts used to identify naïve, switched memory (SM; IgD-,  
 1177 CD27+), unswitched memory (USM; IgD+, CD27+), and double negative (DN) B cells.  
 1178 (C) Box plot of memory and naïve B cell subsets (% of all B cells in a sample) between  
 1179 MS patients compared to controls. (D) UMAP of further clustered GC B cells. (E) S  
 1180 (upper panel) and G2M (lower panel) scores of GC B cell clusters were obtained using  
 1181 Seurat. (F) Violin plot presenting the expression of key transcripts used to identify GC B  
 1182 cell subsets: light zone (LZ), dark zone (DZ.1, DZ.2), and undefined GC B cell cluster  
 1183 (GC.B). *CD3D* expression highlights proliferative T cells (prolif.T). (G) Box plot of GC B  
 1184 cell subsets (% of all GC B cells in the sample) between MS patients and controls. In  
 1185 (C) and (G), an unpaired t-test was used (p-values < 0.05 are shown), and the patient  
 1186 with an active relapse is highlighted with a triangle.




1187

1188 **Fig. 3. GC BCRs in MS dLNs are less clonal**

1189 **(A)** Mushroom plot showing intercellular communication of helper T and Tfr cells  
 1190 (ligand) between naïve, memory GC B cells and plasmablasts (receptor) using  
 1191 NicheNet. The colour of red and blue corresponds to the scaled mean (from 0-1)  
 1192 expression of ligand/receptor, while the size of the circle corresponds to a percentage of  
 1193 cells expressing a particular transcript. Red rectangles highlight intercellular  
 1194 communications emphasized in the Results. Diversity of **(B)** all BCRs, **(C)** BCRs of GC  
 1195 B cells, and **(D)** all TCRs presented by boxplots from two different metrics of measuring

1196 repertoire diversity: normalized Shannon entropy (0 corresponds to monoclonal  
1197 BCRs/TCRs, and 1 corresponds to all BCRs/TCRs would be diverse) and percent of  
1198 unique clonotypes. In each case, an unpaired t-test was used to compare diversity  
1199 estimates between MS patients and controls (p-values < 0.1 are shown with p-values <  
1200 0.05 and < 0.1 considered significant and marginally significant respectively).  
1201




1202

1203 **Fig. 4. EBV, HHV-6B and HHV-7 show higher breadth coverage in dcLNs and EBV**  
1204 **viral load is increased in MS patients compared to controls**

1205 (A) Heatmap illustrates the presence and the percentage of viral reads covering the  
1206 EBV, HHV-6B, HHV-7, B19V, and MCPyV reference sequences (breadth coverage) in  
1207 dcLNs determined using hybrid-capture sequencing. Viral breadth coverages were  
1208 normalized from 0 to 1 separately for each virus, followed by agglomerative hierarchical  
1209 clustering using Euclidean distance and Ward.D2 linkage. Dendrograms show the  
1210 clustering of samples based on the breadth coverage profiles of the above-tested  
1211 viruses. Negative samples for tested viruses are presented in white. (B) Box plot of EBV  
1212 copies per 1 million cells in the saliva of MS patients compared to controls. EBV copy  
1213 numbers were determined using qPCR. An unpaired t-test was used, and the patient  
1214 with an active relapse is highlighted with a triangle.

1215



1216

1217 **Fig. 5. MS patient with an active relapse exhibits altered follicular cell ratios and**  
 1218 **clonally expanded EBV targeting CD8+ T cells**

1219 **(A)** Box plots of GC Tfh / Tfh-like (left) and Tfh / Tfr ratios (right) in the MS patients  
 1220 compared to healthy controls. Tfh is a sum of Tfh-like and GC Tfh cell counts. **(B)** Bar  
 1221 plot of standardized Pearson residuals of cell subset numbers between controls and MS  
 1222 patients without the patient with a relapse using Chi-squared test. Increased (red) and  
 1223 decreased (blue) cell subsets in MS patients compared to healthy controls are  
 1224 highlighted. Dashed red lines at  $\pm 3.65$  correspond to Bonferroni corrected p-values ( $<$   
 1225  $0.00013$ ) in the null distribution of standardized residuals. **(C)** Box plots of plasmablast  
 1226 (left) and GC B cell (right) BCR richness (BCRs of total BCR clonotypes in each  
 1227 sample). **(D)** Box plot of expanded T cell clonotypes of all T cell clones (%) in each  
 1228 sample. **(E)** Stacked bar plot of predicted specificity in expanded T cell clonotypes. The

1229 VDJdb database was scanned for TCRab and b clonotypes using tcrdist3. In A and C-E,  
1230 the patient with an active relapse is highlighted with a triangle.  
1231

1232 **Table 1:** Characteristics of MS patients

1233

ID	Age	Sex	Other diseases	MS type	MRI Barkhoff	Time from onset (months)	Time from last relapse	Time from ivMP (months)	LN size (cm)	EDSS at sample collection	EDSS at 1 year follow up
MS001	20-29	M	asthma, pollen allergy	RRMS	4/4	8	8	-	2,06 X 0,63	0	0
MS002	40-49	M	no	RRMS	4/4	33	3	3	2,00 x 0,22	2.0	1.0
MS003	30-39	F	no	RRMS	3/4	4	4	-	NA	0	0
MS004	30-40	F	no	RRMS	3/5	4	4	-	NA	1	1
MS005	20-29	F	asthma, migrane, mild ankylosing spondylitis	RRMS	3/4	4	4	-	2.2 x 0.53	0	0
MS006	40-49	M	no	RRMS	3/4	75	6	6	NA	1.0	0
MS007	40-49	M	no	RRMS	4/4	36	3	3	1.04 X 0.58	2.5	5.0
MS010	30-39	F	no	PPMS	4/4	24	10	12	0.88 X 0.35	6.0	6.0
MS011	30-39	M	no	RRMS	4/4	48	0	-	1.85 X 0.58	3.5	2.0

1234

1235 Abbreviations: ivMP, intravenous methylprednisolone; EDSS, Expanded Disability

1236 Status Scale; LN, lymph node

1237 **Table 2:** Results from the viral assays  
1238

ID	type	Plasma	Saliva (copies / 1*10 <sup>6</sup> cells)			cLN (breadth of coverage in %)				
		EBV VCA IgG (RU/ml)	EBV	HHV6B	HHV7	EBV	HHV-6B	HHV-7	MCPyV	B19V
CTRL008	CTRL	0	0	82	32400					
CTRL009	CTRL	104,59	387	132	77,1					
CTRL012	CTRL	151	0	0	347	5,13	0	26,4	22.4	89,5
CTRL013	CTRL	63,5	0	17,9	2210	0	0	3,8	3.4	41,2
CTRL014	CTRL	137	0	38,2	525					
CTRL015	CTRL	146,3	0	334	25300	0	0	0	0	12,3
CTRL016	CTRL		0	491	211000	20,8	0	11,4	0	8,4
MS001	MS	172,86	3270	33,8	2030					
MS002	MS	136,26	52,8	314	375	29,9	0	36,8	3,5	6,2
MS003	MS	179,04	0	69,2	11800	28,2	0	1,84	0	3,1
MS004	MS	223,73	26,2	297	3680	14,7	10,12	98,6	0	0
MS005	MS	194,59	17000	219	74100	0	9,5	95,67	6,7	3,5
MS006	MS	179,72	4520	0	221					
MS007	MS	209,72	10,4	15,2	2350					
MS010	MS	153,48	37	0	1890					
MS011	MS	177,19	6660	389	154000					

1239  
1240 Abbreviations: EBV, Epstein-Barr Virus; HHV, human herpes virus; MCPyV, Merkel cell  
1241 polyomavirus; B19V, parvovirus B19  
1242